(19)
(11)EP 2 350 083 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
17.05.2017 Bulletin 2017/20

(21)Application number: 09782789.3

(22)Date of filing:  08.09.2009
(51)Int. Cl.: 
C07D 487/04  (2006.01)
A61P 35/00  (2006.01)
A61K 31/519  (2006.01)
(86)International application number:
PCT/EP2009/061656
(87)International publication number:
WO 2010/026262 (11.03.2010 Gazette  2010/10)

(54)

PYRIMIDO[5,4-D]PYRIMIDINES AS CELL PROLIFERATION INHIBITORS

PYRIMIDO[5,4-D]PYRIMIDINE ALS INHIBITOREN DER ZELLPROLIFERATION

PYRIMIDO[5,4-D]PYRIMIDINES COMME INHIBITEURS DE LA PROLIFÉRATION CELLULAIRE


(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)Priority: 08.09.2008 EP 08163897

(43)Date of publication of application:
03.08.2011 Bulletin 2011/31

(73)Proprietor: Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein (DE)

(72)Inventors:
  • MANTOULIDIS, Andreas
    55216 Ingelheim am Rhein (DE)
  • DAHMANN, Georg
    55216 Ingelheim am Rhein (DE)
  • ETTMAYER, Peter
    55216 Ingelheim am Rhein (DE)
  • KLEIN, Christian
    55216 Ingelheim am Rhein (DE)
  • STEURER, Steffen
    55216 Ingelheim am Rhein (DE)
  • WAIZENEGGER, Irene
    55216 Ingelheim am Rhein (DE)
  • ZAHN, Stephan Karl
    55216 Ingelheim am Rhein (DE)

(74)Representative: Simon, Elke Anna Maria et al
Boehringer Ingelheim GmbH Binger Strasse 173
55216 Ingelheim am Rhein
55216 Ingelheim am Rhein (DE)


(56)References cited: : 
EP-A1- 0 837 063
WO-A1-95/19774
WO-A1-96/40142
WO-A1-97/32882
EP-A1- 1 029 853
WO-A1-96/07657
WO-A1-97/32880
WO-A1-98/02437
  
      
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


    Description


    [0001] The present invention relates to new compounds of general formula (1)

    wherein the groups R1 to R4, X1, X2, X3, L1 and L2 have the meanings given in the claims and specification and the tautomers, racemates, enantiomers, diastereomers and mixtures thereof and the salts of all these forms and their use as medicaments.

    Background to the invention



    [0002] Pyrimido[5,4-d]pyrimidines for inhibiting tyrosinekinases, which are involved in signal transduction, are described in WO 96/07657, WO 97/32880 and WO 97/32882.

    [0003] The aim of the present invention is to discover new active substances which can be used for the prevention and/or treatment of diseases characterised by excessive or abnormal cell proliferation.

    Detailed description of the invention



    [0004] It has now been found that, surprisingly, compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, L1 and L2 have the meanings given hereinafter act as inhibitors of specific signal enzymes which are involved in controlling cell proliferation. Thus, the compounds according to the invention may be used for example for the treatment of diseases connected with the activity of these signal enzymes and characterised by excessive or abnormal cell proliferation.

    [0005] The present invention therefore relates to compounds of general formula (1)

    wherein

    R1 denotes hydrogen or a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
    or
    a suitable substituent, selected from among -ORc, -SRc, -NRcRc, -NRgNRcRc and -S(O)Rc;

    R2 denotes a group optionally substituted by one or more identical or different Rb and/or

    Rc, selected from among C6-10aryl and 5-12 membered heteroaryl;

    R3 is selected from among hydrogen, C1-4alkyl, halogen, -OH, -O(C1-4alkyl), -NH2, -NH(C1-4alkyl) and -N(C1-4alkyl)2;

    R4 denotes fluorine, bromine, chlorine or methyl;

    X1, X2 and X3 each denote CH;

    L1 is selected from among -CH2-, -NH-, -NMe-, -O- and -S-;

    L2 is selected from among -C(O)NH- and -NHC(O)-;

    each Rb is a suitable substituent and is selected independently of one another from among -ORc, -SRc, -NRcRc, -ONRcRc, -N(ORc)Rc, -NRgNRcRc, halogen, -CN, -NO2, -N3, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -C(O)NRgNRcRc, -C(O)NRgORc, -C(NRg)Rc, -N=CRcRc, -C(NRg)ORc, -C(NRg)NRcRc, -C(NRg)NRgNRcRc, -C(NORg)Rc, -C(NORg)NRcRc, -C(NNRgRg)Rc, -OS(O)Rc, -OS(O)ORc, -OS(O)NRcRc, -OS(O)2Rc, -OS(O)2ORc, -OS(O)2NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OC(NRg)Rc, -OC(NRg)NRcRc, -ONRgC(O)Rc, -S(O)Rc, -S(O)ORc, -S(O)NRcRc, -S(O)2Rc, -S(O)20Rc, -S(O)2NRcRc, -NRgC(O)Rc, -NRgC(O)ORc, -NRgC(O)NRcRc, -NRgC(O)NRgNRcRc, -NRgC(NRg)Rc, -N=CRcNRcRc, -NRgC(NRg)ORc, -NRgC(NRg)NRcRc, -NRgC(NORg)Rc, -NRgS(O)Rc, -NRgS(O)ORc, -NRgS(O)2Rc, -NRgS(O)2ORc, -NRgS(O)2NRcRc, -NRgNRgC(O)Rc, -NRgNRgC(O)NRcRc, -NRgNRgC(NRg)Rc and -N(ORg)C(O)Rc and the bivalent substituents =O, =S, =NRg, =NORg, =NNRgRg and =NNRgC(O)NRgRg, while these bivalent substituents may only be substituents in non-aromatic ring systems;

    each Rc independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd and/or Re, selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rd is a suitable substituent and is selected independently of one another from among -ORe, -SRe, -NReRe, -ONReRe, -N(ORe)Re, -N(Rg)NReRe, halogen, -CN, -NO, -NO2, -N3, -C(O)Re, -C(O)ORe, -C(O)NReRe, -C(O)NRgNReRe, -C(O)NRgORe, -C(NRg)Re, -N=CReRe, -C(NRg)ORe, -C(NRg)NReRe, -C(NRg)NRgNReRe, -C(NORg)Re, -C(NORg)NReRe, -C(NNRgRg)Re, -OS(O)Re, -OS(O)ORe, -OS(O)NReRe, -OS(O)2Re, -OS(O)2ORe, -OS(O)2NReRe, -OC(O)Re, -OC(O)ORe, -OC(O)NReRe, -OC(NRg)Re, -OC(NRg)NReRe, -ONRgC(O)Re, -S(O)Re, -S(O)ORe, -S(O)NReRe, -S(O)2Re, -S(O)2ORe, -S(O)2NReRe, -NRgC(O)Re, -NRgC(O)ORe, -NRgC(O)NReRe, -NRgC(O)NRgNReRe, -NRgC(NRg)Re, -N=CReNReRe, -NRgC(NRg)ORe, -NRgC(NRg)NReRe, -NRgC(NRg)SRe, -NRgC(NORg)Re, -NRgS(O)Re, -NRgS(O)ORe, -NRgS(O)2Re, -NRgS(O)2ORe, -NRgS(O)2NReRe, -NRgNRgC(O)Re, -NRgNRgC(O)NReRe, -NRgNRgC(NRg)Re and -N(ORg)C(O)Re and the bivalent substituents =O, =S, =NRg, =NORg, =NNRgRg and =NNRgC(O)NRgRg, while these bivalent substituents may only be substituents in non-aromatic ring systems;

    each Re independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rf and/or Rg, selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rf is a suitable substituent and is selected independently of one another from among -ORg, -SRg, -NRgRg, -ONRgRg, -N(ORg)Rg, -N(Rh)NRgRg, halogen, -CN, -NO2, -N3, -C(O)Rg, -C(O)OR9, -C(O)NRgRg, -C(O)NRhNRgRg, -C(O)NRhORg, -C(NRh)Rg, -N=CRgRg, -C(NRh)ORg, -C(NRh)NRgRg, -C(NRh)NRhNRgRg, -C(NORh)Rg, -C(NORh)NRgRg, -C(NNRhRh)Rg, -OS(O)Rg, -OS(O)OR9, -OS(O)NRgRg, -OS(O)2Rg, -OS(O)2ORg, -OS(O)2NRgRg, -OC(O)Rg, -OC(O)OR9, -OC(O)NRgRg, -OC(NRh)Rg, -OC(NRh)NRgRg, -ONRhC(O)Rg, -S(O)Rg, -S(O)OR9, -S(O)NRgRg, -S(O)2Rg, -S(O)2ORg, -S(O)2NRgRg, -NRhC(O)Rg, -NRhC(O)ORg, -NRhC(O)NRgRg, -NRhC(O)NRhNRgRg, -NRhC(NRh)Rg, -N=CRgNRgRg, -NRhC(NRh)ORg, -NRhC(NRh)NRgRg, -NRhC(NORh)Rg, -NRhS(O)Rg, -NRhS(O)ORg, -NRhS(O)2Rg, -NRhS(O)2ORg, -NRhS(O)2NRgRg, -NRhNRhC(O)Rg, -NRhNRhC(O)NRgRg, -NRhNRhC(NRh)Rg and -N(ORh)C(O)Rg and the bivalent substituents =O, =S, =NRh, =NORh, =NNRhRh and =NNRhC(O)NRhRh, while these bivalent substituents may only be substituents in non-aromatic ring systems;

    each Rg independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rh, selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rh is selected independently of one another from among hydrogen, C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    while the compounds (1) may optionally also be present in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures thereof, or also as pharmacologically acceptable salts of all the above-mentioned forms.



    [0006] In one aspect (A1) the invention relates to compounds (1), wherein
    R3 denotes hydrogen.

    [0007] In another aspect (A2) the invention relates to compounds (1), wherein
    R3 denotes -NH2 or -NHMe.

    [0008] In another aspect (B1) the invention relates to compounds (1), wherein
    R1 denotes hydrogen.

    [0009] In another aspect (A1B1) the invention relates to compounds (1), wherein
    R1 and R3 denote hydrogen.

    [0010] In another aspect (B2) the invention relates to compounds (1), wherein
    R1 is a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl, and Rb and Rc are as hereinbefore defined.

    [0011] In another aspect (B3) the invention relates to compounds (1), wherein
    R1 is a 3-7 membered, monocyclic and nitrogen-containing heterocycloalkyl or 6-10 membered, bicyclic and nitrogen-containing heterocycloalkyl optionally substituted by one or more identical or different Rb and/or Rc,
    R1 is bound to the pyrimido[5,4-d]pyrimidine structure through a nitrogen atom,
    and Rb and Rc are as hereinbefore defined.

    [0012] In another aspect (B4) the invention relates to compounds (1), wherein
    R1 is a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among piperidyl, perhydro-1,4-diazepinyl, piperazinyl, octahydro-pyrrolo[1,2-a]pyrazinyl, 2,5-diazabicyclo[2,2,1]heptyl, octahydro-pyrido[1,2-a]pyrazinyl, perhydro-1,4-oxazepinyl, morpholinyl, pyrrolidinyl, perhydroazepinyl, thiomorpholinyl, thiazolidinyl and azetidinyl,
    R1 is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom,
    and Rb and Rc are as hereinbefore defined.

    [0013] In another aspect (B5) the invention relates to compounds (1), wherein
    R1 is a 2-methyl-2,7-diazaspiro[4.4]nonyl optionally substituted by one or more identical or different Rb and/or Rc, which binds to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom,
    and Rb and Rc are as hereinbefore defined.

    [0014] In another aspect (B6) the invention relates to compounds (1) with one of the structural aspects B2 to B5,
    wherein R1 is heterocycloalkyl which is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom and is optionally substituted by one or more substituents, each independently selected from among Rb1 and Rc1;

    each Rb1 is selected independently of one another from among -ORc1, -NRc1Rc1, halogen, -C(O)Rc1 and =O, while the latter substituent may only be a substituent in non-aromatic ring systems,

    each Rc1 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd1 and/or Re1, selected from among C1-6alkyl, phenyl, C3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,

    each Rd1 is selected independently of one another from among -ORe1 and -NRe1Re1,

    each Re1 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different C1-6alkyl, selected from among C1-6alkyl, C3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.



    [0015] In another aspect (B7) the invention relates to compounds (1), wherein R1 is selected from among







    [0016] In another aspect (B8) the invention relates to compounds (1), wherein
    R1 denotes -NRc2Rc3 and
    Rc2 and Rc3 are each defined as Rc defined hereinbefore.

    [0017] In another aspect (B9) the invention relates to compounds (1), wherein
    R1 denotes -NRc2Rc3 and
    Rc2 is selected from among hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 3-7 membered heterocycloalkyl,
    Rc3 is a group optionally substituted by one or more identical or different Rd3 and/or Re3, selected from among C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl and 3-14 membered heterocycloalkyl,
    each Rd3 is selected independently of one another from among halogen, -NRe3Re3 and -ORe3,
    each Re3 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rf3 and/or Rg3, selected from among C1-6alkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
    each Rf3 denotes -ORg3 and
    each Rg3 are each selected independently of one another from among hydrogen and C1-6alkyl.

    [0018] In another aspect (B10) the invention relates to compounds (1) with one of the structural aspects B8 or B9, wherein
    Rc2 denotes hydrogen.

    [0019] In another aspect (B11) the invention relates to compounds (1), wherein
    R1 is selected from among



    [0020] In another aspect (B12) the invention relates to compounds (1) with one of the structural aspects B8 or B9, wherein
    Rc2 denotes methyl or ethyl.

    [0021] In another aspect (B13) the invention relates to compounds (1), wherein
    R1 is selected from among



    [0022] In another aspect (C1) the invention relates to compounds (1), wherein
    R4 denotes fluorine, bromine, chlorine or methyl.

    [0023] In another aspect (D2) the invention relates to compounds (1), wherein
    X1, X2 and X3 each denote CH.

    [0024] In another aspect (E1) the invention relates to compounds (1), wherein
    L1 denotes -NH- or -NMe-.

    [0025] In another aspect (F1) the invention relates to compounds (1), wherein
    R2 is a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among C6-10aryl and 5-12 membered heteroaryl,
    and Rb and Rc are as hereinbefore defined.

    [0026] In another aspect (F2) the invention relates to compounds (1), wherein
    R2 is a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among phenyl and 5-6 membered heteroaryl,
    and Rb and Rc are as hereinbefore defined.

    [0027] In another aspect (F3) the invention relates to compounds (1), wherein
    R2 is a 5-6 membered heteroaryl optionally substituted by one or more identical or different Rb and/or Rc
    and Rb and Rc are as hereinbefore defined.

    [0028] In another aspect (F4) the invention relates to compounds (1),
    wherein R2 is a heteroaryl which is selected from among furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl and pyrimidyl, and is optionally substituted by one or two substituents, each independently selected from among C3-7cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, 1-methylpropyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, 1-methylbutyl, 1-ethylpropyl, isopentyl, neopentyl, trifluoromethyl, difluoromethyl, fluoromethyl, tert.-butoxy, trifluoromethoxy,





    [0029] In another aspect (F5) the invention relates to compounds (1), wherein
    R2 is a phenyl optionally substituted by one or more identical or different Rb and/or Rc, and Rb and Rc are as hereinbefore defined.

    [0030] In another aspect (F6) the invention relates to compounds (1), wherein R2 denotes a phenyl

    R5 is selected from among hydrogen, C1-6alkyl, -OC1-6alkyl, C1-6haloalkyl, -OC1-6haloalkyl, C3-7cycloalkyl and 3-7 membered heterocycloalkyl, all the above-mentioned groups optionally being substituted by C1-6alkyl, -CN or -OH;

    R6 is selected from among hydrogen, C1-6alkyl, -OC1-6alkyl, C1-6haloalkyl, -OC1-6haloalkyl, -CN, -OH, halogen, -NHC1-6alkyl and -N(C1-6alkyl)2, the latter two optionally being substituted in the alkyl moiety by a substituent -N(C1-6alkyl)2;

    R7 is selected from among hydrogen, -OC1-6alkyl, halogen, -NHS(O)2C1-6alkyl, -S(O)2NH2, -S(O)2NHC1-6alkyl, -S(O)2N(C1-6alkyl)2,



    R9 is selected from among hydrogen and C1-6alkyl;

    Rc4 is hydrogen or a group optionally substituted by one or more identical or different Rd4 and/or Re4, selected from among C1-6alkyl and 3-14 membered heterocycloalkyl;

    each Rd4 is a suitable substituent and is selected independently of one another from among -ORe4, -NRe4Re4 and halogen;

    each Re4 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rf4 and/or Rg4, selected from among C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rf4 is a suitable substituent and is selected independently of one another from among -ORg4, -NRg4Rg4 and halogen as well as the bivalent substituent =O, which may only be a substituent in non-aromatic ring systems;

    each Rg4 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rh4, selected from among C1-6alkyl, C3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rh4 is selected independently of one another from among C1-6alkyl and the bivalent substituent =O, which may only be a substituent in non-aromatic ring systems;
    or

    the group -NR9Rc4 denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among Rd4 and Re4;

    the group -NR9Re4 denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among Rf4 and Rg4;

    the group -NR9Rg4 denotes a nitrogen-containing 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) Rh4; and

    R8 is selected from among hydrogen, C1-6alkyl, -OC1-6alkyl, -CN, halogen, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.



    [0031] In another aspect (F7) the invention relates to compounds (1) with structural aspect F6, wherein
    at least one of the groups R5 to R8 is not hydrogen.

    [0032] In another aspect (F8) the invention relates to compounds (1) with structural aspect F6, wherein
    R5 is selected from among







    [0033] In another aspect (F9) the invention relates to compounds (1), wherein
    R2 is selected from among

    and R' denotes the binding site to the linker unit L2.

    [0034] In another aspect (F10) the invention relates to compounds (1), wherein
    R2 is selected from among













    and R' denotes the binding site to the linker unit L2.

    [0035] In another aspect (F11) the invention relates to compounds (1), wherein
    R2 is selected from among

    and R' denotes the binding site to the linker unit L2,

    [0036] In another aspect (G1) the invention relates to compounds (1), wherein
    L2 denotes (R2)-NHC(O)-,

    [0037] In another aspect (G2) the invention relates to compounds (1), wherein
    L2 denotes (R2)-C(O)NH-,

    [0038] All the above-mentioned structural aspects A to G relating to different molecular parts of the compounds (1) according to the invention may be permutated with one another as desired to form combinations ABCDEFG, so as to obtain preferred compounds (1) . Each combination ABCDEFG represents and defines individual embodiments or generic partial amounts of compounds according to the invention. Every individual embodiment or partial amount defined by this combination is expressly included and is an object of the invention.

    [0039] In another aspect the invention relates to compounds - or the pharmacologically acceptable salts thereof - of general formula (1) as medicaments.

    [0040] In another aspect the invention relates to pharmaceutical preparations, containing as active substance one or more compounds of general formula (1) or the pharmacologically acceptable salts thereof, optionally in combination with conventional excipients and/or carriers.

    [0041] In another aspect the invention relates to compounds of general formula (1) for use in the treatment and/or prevention of cancer, infections, inflammations and autoimmune diseases.

    [0042] In another aspect the invention relates to compounds of general formula (1) for use in the treatment and/or prevention of cancer.

    [0043] In another aspect the invention relates to a pharmaceutical preparation comprising a compound of general formula (1), while the compounds (1) may optionally also be in the form of the tautomers, racemates, enantiomers, diastereomers and mixtures thereof or as the respective pharmacologically acceptable salts of all the above-mentioned forms, and at least one other cytostatic or cytotoxic active substance different from formula (1).

    Definitions


    As used herein, the following definitions apply, unless stated otherwise:



    [0044] The use of the prefix Cx-y, where x and y in each case denote a natural number (x < y), indicates that the chain or cyclic structure or combination of chain and cyclic structure referred to and mentioned in direction connection may consist in total of a maximum of y and a minimum of x carbon atoms.

    [0045] The information as to the number of members in groups containing one or more heteroatom(s) (heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl) refers to the total atomic number of all the ring members or chain members or the total of all the ring and chain members.

    [0046] Alkyl is made up of the sub-groups saturated hydrocarbon chains and unsaturated hydrocarbon chains, while the latter may be further subdivided into hydrocarbon chains with a double bond (alkenyl) and hydrocarbon chains with a triple bond (alkynyl). Alkenyl contains at least one double bond, alkynyl at least one triple bond. If a hydrocarbon chain should have both at least one double bond and at least one triple bond, by definition it belongs to the alkynyl sub-group. All the above-mentioned sub-groups may be further subdivided into straight-chain (unbranched) and branched. If an alkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying carbon atoms. Examples of individual sub-groups are listed below:

    Straight-chain (unbranched) or blanched, saturated hydrocarbon chains:



    [0047] methyl; ethyl; n-propyl; isopropyl (1-methylethyl); n-butyl; 1-methylpropyl; isobutyl (2-methylpropyl); sec.-butyl (1-methylpropyl); tert.-butyl (1.1-dimethylethyl); n-pentyl; 1-methylbutyl; 1-ethylpropyl; isopentyl (3-methylbutyl); neopentyl (2,2-dimethyl-propyl); n-hexyl; 2,3-dimethylbutyl; 2,2-dimethylbutyl; 3,3-dimethylbutyl; 2-methyl-pentyl; 3-methylpentyl; n-heptyl; 2-methylhexyl; 3-methylhexyl; 2,2-dimethylpentyl; 2,3-dimethylpentyl; 2,4-dimethylpentyl; 3,3-dimethylpentyl; 2,2,3-trimethylbutyl; 3-ethylpentyl; n-octyl; n-nonyl; n-decyl etc.

    straight-chained (unbranched) or blanched alkenyl:



    [0048] vinyl (ethenyl); prop-1-enyl; allyl (prop-2-enyl); isopropenyl; but-1-enyl; but-2-enyl; but-3-enyl; 2-methyl-prop-2-enyl; 2-methyl-prop-l-enyl; 1-methyl-prop-2-enyl; 1-methyl-prop-1-enyl; 1-methylidenepropyl; pent-1-enyl; pent-2-enyl; pent-3-enyl; pent-4-enyl; 3-methyl-but-3-enyl; 3-methyl-but-2-enyl; 3-methyl-but-1-enyl; hex-1-enyl; hex-2-enyl; hex-3-enyl; hex-4-enyl; hex-5-enyl; 2,3-dimethyl-but-3-enyl; 2,3-dimethyl-but-2-enyl; 2-methylidene-3-methylbutyl; 2,3-dimethyl-but-1-enyl; hexa-1,3-dienyl; hexa-1,4-dienyl; penta-1,4-dienyl; penta-1,3-dienyl; buta-1,3-dienyl; 2,3-dimethylbuta-1,3-diene etc.

    straight-chain (unbranched) or blanched alkynyl:



    [0049] ethynyl; prop-1-ynyl; prop-2-ynyl; but-1-ynyl; but-2-ynyl; but-3-ynyl; 1-methyl-prop-2-ynyl etc.

    [0050] By the terms propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl etc. unless otherwise stated are meant saturated hydrocarbon groups with the corresponding number of carbon atoms, including all the isomeric forms.

    [0051] By the terms propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl etc. unless otherwise stated are meant unsaturated hydrocarbon groups with the corresponding number of carbon atoms and a double bond, including all the isomeric forms, also (Z)/(E)-isomers, where applicable.

    [0052] By the terms butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl etc. unless otherwise stated are meant unsaturated hydrocarbon groups with the corresponding number of carbon atoms and two double bonds, including all the isomeric forms, also (Z)/(E)-isomers, where applicable.

    [0053] By the terms propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl etc. unless otherwise stated are meant unsaturated hydrocarbon groups with the corresponding number of carbon atoms and a triple bond, including all the isomeric forms.

    [0054] From alkyl as hereinbefore defined and its subgroups the term alkylene can also be derived. Alkylene unlike alkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from an alkyl. Corresponding groups are for example -CH3 and -CH2, -CH2CH3 and -CH2CH2 or >CHCH3 etc. For all the subgroups of alkyl there are correspondences for alkylene.

    [0055] By heteroatoms are meant oxygen, nitrogen and sulphur atoms.

    [0056] By the term heteroalkyl are meant groups which are derived from the alkyl as hereinbefore defined in its widest sense by replacing, in the hydrocarbon chains, one or more of the groups -CH3 independently of one another by the groups -OH, -SH or -NH2, one or more of the groups -CH2- independently of one another by the groups -O-, -S- or -NH-, one or more of the groups >CH- by the group >N-, one or more of the groups =CH- by the group =N-, one or more of the groups =CH2 by the group =NH or one or more of the groups ≡CH by the group ≡N, while a total of not more than three heteroatoms may be present in one heteroalkyl, there must be at least one carbon atom between two oxygen atoms and between two sulphur atoms or between one oxygen and one sulphur atom and the group as a whole must have chemical stability.

    [0057] A direct result of the indirect definition/derivation from alkyl is that heteroalkyl is made up of the sub-groups saturated hydrocarbon chains with heteroatom(s), heteroalkenyl and heteroalkynyl, and it may be further subdivided into straight-chain (unbranched) and branched. If a heteroalkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying oxygen, sulphur, nitrogen and/or carbon atoms. Heteroalkyl itself as a substituent may be attached to the molecule both through a carbon atom and through a heteroatom. The following are listed by way of example:

    dimethylaminomethyl; dimethylaminoethyl (1- dimethylaminoethyl; 2-dimethyl-aminoethyl); dimethylaminopropyl (1-dimethylaminopropyl, 2-dimethylaminopropyl, 3-dimethylaminopropyl); diethylaminomethyl; diethylaminoethyl (1-diethylaminoethyl, 2-diethylaminoethyl); diethylaminopropyl (1-diethylaminopropyl, 2- diethylamino-propyl, 3-diethylaminopropyl); diisopropylaminoethyl (1-diisopropylaminoethyl, 2-diisopropylaminoethyl); bis-2-methoxyethylamino; [2-(dimethylamino-ethyl)-ethyl-amino]-methyl; 3-[2-(dimethylamino-ethyl)-ethyl-amino]-propyl; hydroxymethyl; 2-hydroxy-ethyl; 3-hydroxypropyl; methoxy; ethoxy; propoxy; methoxymethyl; 2-methoxyethyl etc.



    [0058] From heteroalkyl as hereinbefore defined and its subgroups the term heteroalkylene can also be derived. Heteroalkylene unlike heteroalkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a heteroalkyl. Corresponding groups are for example -CH2NH2 and -CH2NH- or >CHNH2, -NHCH3 and >NCH3 or -NHCH2-, -CH2OCH3 and -CH2OCH2- or >CHOCH3 etc. For all the subgroups of heteroalkyl there are correspondences for heteroalkylene.

    [0059] Haloalkyl is derived from alkyl as hereinbefore defined in its broadest sense, by replacing one or more hydrogen atoms of the hydrocarbon chain independently of one another by halogen atoms, which may be identical or different. A direct result of the indirect definition/derivation from alkyl is that haloalkyl is made up of the sub-groups saturated hydrohalogen chains, haloalkenyl and haloalkynyl, and it may be further subdivided into straight-chain (unbranched) and branched. If a haloalkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying carbon atoms. Typical examples are listed below:
    • CF3; -CHF2; -CH2F; -CF2CF3; -CHFCF3; -CH2CF3; -CF2CH3; -CHFCH3; -CF2CF2CF3; -CF2CH2CH3; -CF=CF2; -CCl=CH2; -CBr=CH2; -CI=CH2; -C≡C-CF3; -CHFCH2CH3; -CHFCH2CF3 etc.


    [0060] From haloalkyl as hereinbefore defined and its subgroups the term haloalkylene can also be derived. Haloalkylene unlike haloalkyl is bivalent and requires two bonding partners.

    [0061] Formally the second valency is produced by removing a hydrogen atom from a haloalkyl. Corresponding groups are for example -CH2F and -CHF-, -CHFCH2F and -CHFCHF- or >CFCH2F etc. For all the subgroups of haloalkyl there are correspondences for haloalkylene.

    [0062] Halogen encompasses fluorine, chlorine, bromine and/or iodine atoms.

    [0063] Cycloalkyl is made up of the sub-groups monocyclic hydrocarbon rings, bicyclic hydrocarbon rings and spirohydrocarbon rings, while each sub-group may be further subdivided into saturated and unsaturated (cycloalkenyl). By unsaturated is meant that there is at least one double bond in the ring system, but no aromatic system is formed. In bicyclic hydrocarbon rings two rings are linked such that they share at least two carbon atoms. In spirohydrocarbon rings one carbon atom (spiroatom) is shared by two rings. If a cycloalkyl is substituted, it may be mono- or polysubstituted independently of one another at all the hydrogen-carrying carbon atoms. Cycloalkyl itself as a substituent may be attached to the molecule through any suitable position of the ring system. The following individual sub-groups are listed by way of example:

    monocyclic hydrocarbon rings, saturated:



    [0064] cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl etc.

    monocyclic hydrocarbon rings, unsaturated:



    [0065] cycloprop-1-enyl; cycloprop-2-enyl; cyclobut-1-enyl; cyclobut-2-enyl; cyclopent-1-enyl; cyclopent-2-enyl; cyclopent-3-enyl; cyclohex-1-enyl; cyclohex-2-enyl; cyclohex-3-enyl; cyclohept-1-enyl; cyclohept-2-enyl; cyclohept-3-enyl; cyclohept-4-enyl; cyclobuta-1,3-dienyl; cyclopenta-1,4-dienyl; cyclopenta-1,3-dienyl; cyclopenta-2,4-dienyl; cyclohexa-1,3-dienyl; cyclohexa-1,5-dienyl; cyclohexa-2,4-dienyl; cyclohexa-1,4-dienyl; cyclohexa-2,5-dienyl etc.

    bicyclic hydrocarbon rings (saturated and unsaturated):



    [0066] bicyclo[2.2.0]hexyl; bicyclo[3.2.0]heptyl; bicyclo[3.2.1]octyl; bicyclo[2.2.2]octyl; bicyclo[4.3.0]nonyl (octahydroindenyl); bicyclo[4.4.0]decyl (decahydronaphthalene); bicyclo[2.2.1]heptyl (norbornyl); (bicyclo[2.2.1]hepta-2,5-dienyl (norborna-2,5-dienyl); bicyclo[2.2.1]hept-2-enyl (norbornenyl); bicyclo[4.1.0]heptyl (norcaranyl); bicyclo-[3.1.1]heptyl (pinanyl) etc.

    spirohydrocarbon rings (saturated and unsaturated):



    [0067] spiro[2.5]octyl, spiro[3.3]heptyl, spiro[4.5]dec-2-ene, etc.

    [0068] If the free valency of a cycloalkyl is saturated off, an alicyclic ring is obtained.

    [0069] From cycloalkyl as hereinbefore defined and its subgroups the term cycloalkylene can also be derived. Cycloalkylene unlike cycloalkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a cycloalkyl. Corresponding groups are for example cyclohexyl and

    or

    cyclopentenyl and

    or

    etc.

    [0070] For all the subgroups of cycloalkyl there are correspondences for cycloalkylene.

    [0071] Cycloalkylalkyl refers to the combination of the alkyl in question, as hereinbefore defined, with cycloalkyl, both in their widest sense. Alternatively cycloalkylalkyl may also be regarded as a combination of cycloalkyl with alkylene. Formally, cycloalkylalkyl is obtained by first linking an alkyl as substituent directly with the molecule and then substituting with a cycloalkyl. The linking of alkyl and cycloalkyl may be carried out in both groups using carbon atoms that are suitable for this purpose. The respective subgroups of alkyl (alkylene) and cycloalkyl are also included in the combination of the two groups.

    [0072] Aryl denotes mono-, bi- or tricyclic carbon rings with at least one aromatic ring. If an aryl is substituted, the substitution may be mono- or polysubstitution in each case, at all the hydrogen-carrying carbon atoms, independently of one another. Aryl itself may be linked to the molecule as substituent via any suitable position of the ring system. Typical examples are listed below:

    phenyl, naphthyl, indanyl (2,3-dihydroindenyl), 1,2,3,4-tetrahydronaphthyl; fluorenyl, etc.



    [0073] If the free valency of an aryl is saturated off, an aromatic group is obtained.

    [0074] From aryl as hereinbefore defined the term arylene can also be derived. Arylene unlike aryl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from an aryl. Corresponding groups are for example phenyl and

    naphthyl and

    or

    etc. For all the subgroups of aryl there are correspondences for arylene.

    [0075] Arylalkyl denotes the combination of the groups alkyl and aryl as hereinbefore defined, in each case in their broadest sense. Alternatively arylalkyl may also be regarded as a combination of aryl with alkylene. Formally, arylalkyl is obtained by first linking an alkyl as substituent directly to the molecule and substituting it with an aryl group. The alkyl and aryl may be linked in both groups via any carbon atoms suitable for this purpose. The respective sub-groups of alkyl (alkylene) and aryl are also included in the combination of the two groups. Typical examples are listed below:

    benzyl; 1-phenylethyl; 2-phenylethyl; phenylvinyl; phenylallyl etc.



    [0076] Heteroaryl denotes monocyclic aromatic rings or polycyclic rings with at least one aromatic ring, which, compared with corresponding aryl or cycloalkyl, contain instead of one or more carbon atoms one or more identical or different heteroatoms, selected independently of one another from among nitrogen, sulphur and oxygen, while the resulting group must be chemically stable. The prerequisite for the presence of heteroaryl is a heteroatom and an aromatic system, although it need not necessarily be a heteroaromatic system. Thus 2,3-dihydro-1H-indol-6-yl

    may according to the definition be a heteroaryl.

    [0077] If a heteroaryl is substituted, the substitution may be mono- or polysubstitution in each case, at all the hydrogen-carrying carbon and/or nitrogen atoms, independently of one another. Heteroaryl itself as substituent may be linked to the molecule via any suitable position of the ring system, both carbon and nitrogen. Typical examples are listed below.

    monocyclic heteroaryls:



    [0078] furyl; thienyl; pyrrolyl; oxazolyl; thiazolyl; isoxazolyl; isothiazolyl; pyrazolyl; imidazolyl; triazolyl; tetrazolyl; oxadiazolyl; thiadiazolyl; pyridyl; pyrimidyl; pyridazinyl; pyrazinyl; triazinyl; pyridyl-N-oxide; pyrrolyl-N-oxide; pyrimidinyl-N-oxide; pyridazinyl-N-oxide; pyrazinyl-N-oxide; imidazolyl-N-oxide; isoxazolyl-N-oxide; oxazolyl-N-oxide; thiazolyl-N-oxide; oxadiazolyl-N-oxide; thiadiazolyl-N-oxide; triazolyl-N-oxide; tetrazolyl-N-oxide etc.

    polycyclic heteroaryls



    [0079] indolyl; isoindolyl; benzofuryl; benzothienyl; benzoxazolyl; benzothiazolyl; benzisoxazolyl; dihydroindolyl; benzisothiazolyl; benzimidazolyl; indazolyl; isoquinolinyl; quinolinyl; quinoxalinyl; cinnolinyl; phthalazinyl; quinazolinyl; benzotriazinyl; indolizinyl; oxazolopyridyl; imidazopyridyl; naphthyridinyl; indolinyl; isochromanyl; chromanyl; tetrahydroisoquinolinyl; isoindolinyl; isobenzotetrahydrofuryl; isobenzotetrahydrothienyl; isobenzothienyl; benzoxazolyl; pyridopyridyl; benzotetrahydrofuryl; benzotetrahydro-thienyl; purinyl; benzodioxolyl; phenoxazinyl; phenothiazinyl; pteridinyl; benzothiazolyl; imidazopyridyl; imidazothiazolyl; dihydrobenzisoxazinyl; benzisoxazinyl; benzoxazinyl; dihydrobenzisothiazinyl; benzopyranyl; benzothiopyranyl; coumarinyl; isocoumarinyl; chromonyl; chromanonyl; tetrahydroquinolinyl; dihydroquinolinyl; dihydroquinolinonyl; dihydroisoquinolinonyl; dihydrocoumarinyl; dihydroisocoumarinyl; isoindolinonyl; benzodioxanyl; benzoxazolinonyl; quinolinyl-N-oxide; indolyl-N-oxide; indolinyl-N-oxide; isoquinolyl-N-oxide; quinazolinyl-N-oxide; quinoxalinyl-N-oxide; phthalazinyl-N-oxide; indolizinyl-N-oxide; indazolyl-N-oxide; benzothiazolyl-N-oxide; benzimidazolyl-N-oxide; benzothiopyranyl-S-oxide and benzothiopyranyl-S,S-dioxide etc.

    [0080] If the free valency of a heteroaryl is saturated off, a heteroaromatic group is obtained.

    [0081] From heteroaryl as hereinbefore defined the term heteroarylene can also be derived. Heteroarylene unlike heteroaryl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a heteroaryl.

    [0082] Corresponding groups are for example pyrrolyl and

    or

    2,3-dihydro-1H-indolyl and

    or

    etc.

    [0083] For all the subgroups of heteroaryl there are correspondences for heteroarylene.

    [0084] Heteroarylalkyl denotes the combination of the alkyl in question as hereinbefore defined with heteroaryl, both in their broadest sense. Alternatively heteroarylalkyl may also be regarded as a combination of heteroaryl with alkylene. Formally heteroarylalkyl is obtained by first linking an alkyl as substituent directly with the molecule and then substituting it with a heteroaryl. The linking of the alkyl and heteroaryl may be achieved on the alkyl side via any carbon atoms suitable for this purpose and on the heteroaryl side via any carbon or nitrogen atoms suitable for this purpose. The respective sub-groups of alkyl (alkylene) and heteroaryl are also included in the combination of the two groups.

    [0085] By the term heterocycloalkyl are meant groups which are derived from the cycloalkyl as hereinbefore defined if in the hydrocarbon rings one or more of the groups -CH2- are replaced independently of one another by the groups -O-, -S- or -NH- or one or more of the groups =CH- are replaced by the group =N-, while not more than five heteroatoms may be present in total, there must be at least one carbon atom between two oxygen atoms and between two sulphur atoms or between one oxygen and one sulphur atom and the group as a whole must be chemically stable. Heteroatoms may simultaneously be present in all the possible oxidation stages (sulphur → sulphoxide -SO-, sulphone -SO2-; nitrogen → N-oxide). It is immediately apparent from the indirect definition/derivation from cycloalkyl that heterocycloalkyl is made up of the sub-groups monocyclic hetero-rings, bicyclic hetero-rings and spirohetero-rings, while each sub-group can also be further subdivided into saturated and unsaturated (heterocycloalkenyl). The term unsaturated means that in the ring system in question there is at least one double bond, but no aromatic system is formed. In bicyclic hetero-rings two rings are linked such that they have at least two atoms in common. In spirohetero-rings one carbon atom (spiroatom) is shared by two rings. If a heterocycloalkyl is substituted, the substitution may be mono- or polysubstitution in each case, at all the hydrogen-carrying carbon and/or nitrogen atoms, independently of one another. Heterocycloalkyl itself as substituent may be linked to the molecule via any suitable position of the ring system. Typical examples of individual sub-groups are listed below.

    monocyclic heterorings (saturated and unsaturated):



    [0086] tetrahydrofuryl; pyrrolidinyl; pyrrolinyl; imidazolidinyl; thiazolidinyl; imidazolinyl; pyrazolidinyl; pyrazolinyl; piperidinyl; piperazinyl; oxiranyl; aziridinyl; azetidinyl; 1,4-dioxanyl; azepanyl; diazepanyl; morpholinyl; thiomorpholinyl; homomorpholinyl; homopiperidinyl; homopiperazinyl; homothiomorpholinyl; thiomorpholinyl-S-oxide; thiomorpholinyl-S,S-dioxide; 1,3-dioxolanyl; tetrahydropyranyl; tetrahydrothiopyranyl; [1,4]-oxazepanyl; tetrahydrothienyl; homothiomorpholinyl-S,S-dioxide; oxazolidinonyl; dihydropyrazolyl; dihydropyrrolyl; dihydropyrazinyl; dihydropyridyl; dihydropyrimidinyl; dihydrofuryl; dihydropyranyl; tetrahydrothienyl-S-oxide; tetrahydrothienyl-S,S-dioxide; homothiomorpholinyl-S-oxide; 2,3-dihydroazet; 2H-pyrrolyl; 4H-pyranyl; 1,4-dihydropyridinyl etc.

    bicyclic heterorings (saturated and unsaturated):



    [0087] 8-azabicyclo[3.2.1]octyl; 8-azabicyclo[5.1.0]octyl; 2-oxa-5-azabicyclo[2.2.1]heptyl; 8-oxa-3-aza-bicyclo[3.2.1]octyl; 3,8-diaza-bicyclo[3.2.1]octyl; 2,5-diaza-bicyclo-[2.2.1]heptyl; 1-aza-bicyclo[2.2.2]octyl; 3,8-diaza-bicyclo[3.2.1]octyl; 3,9-diaza-bicyclo[4.2.1]nonyl; 2,6-diaza-bicyclo[3.2.2]nonyl etc.

    spiro-heterorings (saturated and unsaturated):



    [0088] 1,4-dioxa-spiro[4.5]decyl; 1-oxa-3.8-diaza-spiro[4.5]decyl; and 2,6-diaza-spiro[3.3]heptyl; 2,7-diaza-spiro[4.4]nonyl; 2,6-diaza-spiro[3.4]octyl; 3,9-diaza-spiro[5.5]undecyl; 2,8-diaza-spiro[4.5]decyl etc.

    [0089] If the free valency of a heterocycloalkyl is saturated off, then a heterocyclic ring is obtained.

    [0090] From heterocycloalkyl as hereinbefore defined the term heterocycloalkylene can also be derived. Heterocycloalkylene unlike heterocycloalkyl is bivalent and requires two bonding partners. Formally the second valency is produced by removing a hydrogen atom from a heterocycloalkyl. Corresponding groups are for example piperidinyl and

    2,3-dihydro-1H-pyrrolyl and

    or

    etc. For all the subgroups of heterocycloalkyl there are correspondences for heterocycloalkylene.

    [0091] Heterocycloalkylalkyl denotes the combination of the alkyl in question as hereinbefore defined with heterocycloalkyl, both in their broadest sense. Alternatively heterocycloalkylalkyl may also be regarded as a combination of heterocycloalkyl with alkylene. Formally heterocycloalkyl is obtained by first linking an alkyl as substituent directly with the molecule and then substituting it with a heterocycloalkyl. The linking of the alkyl and heterocycloalkyl may be achieved on the alkyl side via any carbon atoms suitable for this purpose and on the heterocycloalkyl side via any carbon or nitrogen atoms suitable for this purpose. The respective sub-groups of alkyl and heterocycloalkyl are also included in the combination of the two groups.

    [0092] By is substituted is meant that a hydrogen atom that is bound directly to the atom under consideration is replaced by another atom or another group of atoms (substituent). Depending on the starting conditions (number of hydrogen atoms) mono- or polysubstitution may take place at an atom.

    [0093] Bivalent substituents such as for example =S, =NR, =NOR, =NNRR, =NN(R)C(O)NRR, =N2 or the like may only be substituents at carbon atoms, while the bivalent substituent =O may also be a substituent of sulphur. Generally speaking, substitution by a bivalent substituent may only take place at ring systems and requires exchange for two geminal hydrogen atoms, i.e. hydrogen atoms that are bound to the same carbon atom saturated before the substitution. Substitution by a bivalent substituent is therefore only possible at the group -CH2- or sulphur atoms of a ring system.

    [0094] In addition to this, the term "suitable substituent" denotes a substituent which on the one hand is suitable on account of its valency and on the other hand leads to a system with chemical stability.

    [0095] The following are some abbreviated notations and their structural correspondences:









    [0096] If for example in the sequence A-B-C the member B were to correspond to the structural detail -N=, this is to be understood as both A=N-C and A-N=C

    [0097] If for example in the sequence

    the member A were to correspond to the structural detail >C= this is to be understood as being



    [0098] In a diagram such as for example

    the dotted line indicates that the ring system may be attached to the molecule via the carbon 1 or 2, i.e. is equivalent to the following diagram



    [0099] For bivalent groups where the valency with which they bind which adjacent group is critical, the corresponding binding partners are given in brackets, wherever it is necessary for clarification, as in the following formulae:

    or (R2)-C(O)NH- or (R2)-NHC(O)-; Groups or substituents are frequently selected from among alternative groups/ substituents with a corresponding group designation (e.g. Ra, Rb etc). If a group of this kind is used repeatedly to define a compound according to the invention in different parts of the molecule, it should always be borne in mind that the respective uses are to be regarded as being totally independent of one another.
    List of abbreviations
    Ac acetyl
    ATP adenosine triphosphate
    Bn benzyl
    Boc tert.-butyloxycarbonyl
    Bu butyl
    c concentration
    chex cyclohexane
    d day(s)
    TLC thin layer chromatography
    DCM dichloromethane
    DEA diethylamine
    DIPEA N-ethyl-N,N-diisopropylamine (HÜNIG base)
    DMAP 4-N,N-dimethylaminopyridine
    DME 1,2-dimethoxyethane
    DMF N,N-dimethylformamide
    DMSO dimethylsulphoxide
    DPPA diphenylphosphorylazide
    EDTA ethylenediaminetetraacetic acid
    EE ethyl acetate
    EGTA ethyleneglycoltetraacetic acid
    eq equivalent(s)
    ESI electron spray ionization
    Et ethyl
    Et2O diethyl ether
    EtOH ethanol
    h hour
    HATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium hexafluorophosphate
    hex hexyl
    HPLC high performance liquid chromatography
    Hunig base N-ethyl-N,N-diisopropylamine
    i iso
    cat. catalyst, catalytically
    conc. concentrated
    LC liquid chromatography
    sln. solution
    mCPBA meta-chloroperbenzoic acid
    Me methyl
    MeOH methanol
    min minutes
    MPLC medium pressure liquid chromatography
    MS mass spectrometry
    NMP N-methylpyrrolidone
    NP normal phase
    n.a. not available
    PBS phosphate-buffered saline
    Ph phenyl
    PMSF benzylsulphonic acid fluoride
    Pr propyl
    Py pyridine
    rac racemic
    red. reduction
    Rf (Rf) retention factor
    RP reversed phase
    RT room temperature
    SN nucleophilic substitution
    TBAF tetrabutylammonium fluoride
    TBME tert-butylmethylether
    TBTU O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium tetrafluoroborate
    TEA triethylamine
    temp. temperature
    tert. tertiary
    Tf triflate
    TFA trifluoroacetic acid
    THF tetrahydrofuran
    TMS trimethylsilyl
    tRet. retention time (HPLC)
    TRIS tris(hydroxymethyl)-aminomethane
    TsOH para-toluenesulphonic acid
    UV ultraviolet


    [0100] Features and advantages of the present invention will become apparent from the following detailed Examples, which illustrate the fundamentals of the invention by way of example, without restricting its scope:

    Preparation of the compounds according to the invention


    General



    [0101] Unless stated otherwise, all the reactions are carried out in commercially obtainable apparatus using methods that are commonly used in chemical laboratories. Starting materials that are sensitive to air and/or moisture are stored under protective gas and corresponding reactions and manipulations therewith are carried out under protective gas (nitrogen or argon).

    [0102] Microwave reactions are carried out in an initiator/reactor made by Biotage or in an Explorer made by CEM in sealed containers (preferably 2, 5 or 20 mL), preferably with stirring.

    Chromatography



    [0103] For preparative medium pressure chromatography (MPLC, normal phase) silica gel made by Millipore (name: Granula Silica Si-60A 35-70 µm) or C-18 RP-silica gel (RP-phase) made by Macherey Nagel (name: Polygoprep 100-50 C18) is used. Automated normal phase chromatography is also carried out on a CombiFlash Companion XL apparatus in combination with a CombiFlash Foxy 200 fraction collector made by Isco.

    [0104] For this, commercially obtainable RediSepRf (120 g silica gel) one-way columns are used. The thin layer chromatography is carried out on ready-made silica gel 60 TLC plates on glass (with fluorescence indicator F-254) made by Merck.

    [0105] The preparative high pressure chromatography (HPLC) of the example compounds according to the invention is carried out with columns made by Waters (names: XTerra Prep. MS C18, 5 µm, 30 x 100 mm or XTerra Prep. MS C18, 5 µm, 50 x 100 mm OBD or Symmetric C18, 5 µm, 19 x 100 mm or Sunfire C18 OBD, 19 x 100 mm, 5 µm or Sunfire Prep C10 µm OBD 50 x 150 mm or X-Bridge Prep C18 5 µm OBD 19 x 50 mm), Agilent (name: Zorbax SB-C8 5 µm PrepHT 21.2 x 50 mm) and Phenomenex (names: Gemini C18 5 µm AXIA 21.2 x 50 mm or Gemini C18 10 µm 50 x 150 mm). Different gradients of H2O/acetonitrile or H2O/MeOH are used to elute the compounds, while 0.1 % HCOOH is added to the water.

    [0106] The preparative high pressure chromatography (HPLC) on normal phase of the example compounds according to the invention is carried out with columns made by Macherey & Nagel (name: Nucleosil, 50-7, 40 x 250 mm) and VDSoptilab (name: Kromasil 100 NH2, 10 µM, 50 x 250 mm). Different gradients of DCM/MeOH are used to elute the compounds, while 0.1 % NH3 is added to the MeOH.

    [0107] The analytical HPLC (reaction control) of intermediate compounds is carried out using columns made by Agilent (names: Zorbax SB-C8, 5 µm, 21.2 x 50 mm or Zorbax SB-C8 3.5 µm 2.1 x 50 mm) and Phenomenex (name: Gemini C18 3 µm 2 x 30 mm). The analytical equipment is also equipped with a mass detector in each case.

    HPLC-mass spectroscopy/UV-spectrometry



    [0108] The retention times/MS-ESI+ for characterising the example compounds according to the invention are produced using different HPLC-MS apparatus (high performance liquid chromatography with mass detector). Compounds that elute at the injection peak are given the retention time tRet. = 0.00.

    Details of the methods:



    [0109] 
    HPLC-MS method 1
    HPLC: Agilent 1100 Series
    MS: Agilent LC/MSD SL
    Column: Waters, Xterra MS C18, 2.5 µm, 2.1 x 30 mm, Part.No. 186000592
    Eluant: A: H2O with 0.1 % HCOOH; B: acetonitrile (HPLC grade)
    Detection: MS: Positive and negative mode
    Mass range: 120 - 900 m/z
    Flow 1.10 mL/min
    Column temp.: 40°C
    Gradient: 0.00 min: 5 % eluant B
      0.00 - 2.50 min: 5 % → 95 % eluant B
      2.50 - 2.80 min: 95 % eluant B
      2.81 - 3.10 min: 95 % → 5 % eluant B
    HPLC-MS method 2
    HPLC: HP 1100
    MS: Waters ZQ2000
    Column: Waters, Sunfire C18, 3.5 µm, 4.6 x 50 mm
    Eluant: A: H2O with 0.1 % TFA; B: acetonitrile with 0.1 % TFA (in each case HPLC grade)
    Detection: MS: positive mode
    Mass range: 120 - 820 m/z
    Flow 1.5 mL/min
    Column temp.: 40°C
    Gradient: 0.00 min: 5 % eluant B
      0.00 - 2.00 min: 5 % → 100 % eluant B
      2.00 - 2.50 min: 100 % eluant B
      2.50 - 2.60 min: 100 % → 5 % eluant B
    HPLC-MS-method 3
    HPLC: HP 1100
    MS: Waters ZQ2000
    Column: Supelco, Ascentis C18, 2.7 µm, 4.6 x 50 mm
    Eluant: A: H2O with 0.1 % TFA; B: acetonitrile with 0.1 % TFA (in each case HPLC grade)
    Detection: MS: Positive mode
    Mass range: 120 - 820 m/z
    Flow 1.5 mL/min
    Column temp.: 40°C
    Gradient: 0.00 min: 5 % eluant B
      0.00 - 2.00 min: 5 % → 100 % eluant B
      2.00 - 2.50 min: 100 % eluant B
      2.50 - 2.60 min: 100 % → 5 % eluant B


    [0110] The compounds according to the invention are prepared by the methods of synthesis described hereinafter, in which the substituents of the general formulae have the meanings given hereinbefore. These methods are intended as an illustration of the invention, without restricting its subject matter and the scope of the compounds claimed to these examples. Where the preparation of starting compounds is not described, they are commercially obtainable or may be prepared analogously to known compounds or methods described herein. Substances described in the literature are prepared according to the published methods of synthesis.


    Example compounds of type I:



    [0111] Trisubstituted pyrimidopyrimidines I may be obtained for example by two alternative methods according to Reaction scheme A (synthesis route 1 or 2).

    [0112] Starting from 2,4,8-trichloro-pyrimido[5,4-d]pyrimidine P-1a the chlorine atoms are successively substituted. In the first step the substitution is carried out using ammonia in the 4-position. In the second step the 8-position of the intermediate products P-2a is substituted by the aniline components A-1 or A-2, preferably under basically catalysed conditions at elevated temperature.

    [0113] If A-1 is used the complete left-hand molecular part of the end compounds I is thereby introduced into the intermediate compound Z-2, so that finally there only remains the substitution in the 2-position by components R1-H (E-3), which are preferably primary and secondary (also cyclic) amines and alcohols (in the form of the alkoxides). The components A-1 are obtained by amide coupling of the nitrocarboxylic acids E-1 with amines E-2 to form the intermediate product Z-1 and subsequent reduction of the nitro group. To carry out the amide coupling common coupling reagents as used in peptide chemistry (e.g. HATU or TBTU), are optionally used or the nitro acids E-1 are activated in some other way, e.g. as acid halides (e.g. with thionyl chloride, oxalyl chloride, GHOSEZ reagent).

    [0114] By contrast, by using A-2 first of all only the central phenyl or heteroaryl ring and a protected linker fragment (carboxylate) of the later linker L2 (e.g. amide) is incorporated , before the group R1 is introduced analogously. Therefore in this case additional reaction steps (saponification, activation, amidation) are needed to obtain compounds I. The amide coupling is carried out as described hereinbefore for the nitro acids E-1.

    [0115] Alternatively to P-1a other educts P-1 are possible which allow successive and selective substitution, i.e. have other leaving groups.

    [0116] Both the group R1 and the group R2 of compounds I according to the invention may be modified in other reaction steps (not shown), to obtain other compounds I according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

    a) Method for synthesizing P-1a:



    [0117] 



    [0118] 2,4,8-trihydroxy-pyrimido[5,4-d]pyrimidine (40 g, 222 mmol), potassium chloride (1.68 g, 22.53 mmol) and phosphorus pentachloride (152 g, 730 mmol) are placed in phosphorus oxychloride (240 mL). The reaction mixture is refluxed for 5 h. After cooling the mixture is evaporated down, the residue is triturated several times with petroleum ether and decanted off. The precipitate remaining is mixed with ice water, suction filtered, dissolved in DCM, dried on sodium sulphate and filtered off. The mother liquor is mixed with activated charcoal and heated. The activated charcoal is suction filtered, the filtrate is filtered through silica gel, washed with DCM, evaporated down using the rotary evaporator and 2,4,8-trichloro-pyrimido[5,4-d]pyrimidine P-1a (HPLC-MS: MS (M+H)+ = 234/236/238/240) is obtained. P-1a is used further without any further purification (purity approx. 95 %).

    b) Method for synthesizing P-2a:



    [0119] 



    [0120] P-1a (95 %; 4.0 g, 16.14 mmol) is placed in THF (350 mL) and TEA (2.26 mL, 16.14 mmol). The reaction mixture is cooled to approx. -65°C with a bath of acetone and dry ice. Then ammonia (0.5 M in dioxane; 41.96 mL, 20.98 mmol) is slowly added dropwise. The reaction mixture is stirred further and slowly heated to RT. After 16 h the reaction mixture is evaporated down, the residue is taken up in 300 mL EE and extracted with 1x 200 mL and 2 x 100 mL water. The organic phase is dried on MgSO4, filtered and evaporated down using the rotary evaporator. The intermediate product P-2a (HPLC-MS: tRet. = 0.92 min; MS (M+H)+ = 216/218) is further reacted directly.

    c) Method for synthesizing A-1a:



    [0121] 



    [0122] 4-methyl-3-nitrobenzoic acid E-1a (2.0 g, 11 mmol) is taken up in DCM (40 mL) and mixed with TEA (5.1 mL, 27.6 mmol) and TBTU (3.9 g, 12.2 mmol). After 10 min 4-methoxy-3-trifluoromethylaniline E-2a (2.11 g, 11 mmol) is added and the mixture is stirred for another 2 h at RT. The precipitate formed is filtered off, washed repeatedly with water, dried and Z-1a (MS (M+H)+ = 355) is obtained.

    [0123] The aromatic nitro compound Z-1a (3.5 g, 9.9 mmol) is taken up in EtOH (30 mL), mixed with an ammonium chloride solution (264 mg, 4.94 mmol in 20 mL H2O) and heated to 70°C. At this temperature iron powder (5.52 g, 99 mmol) is added batchwise and the mixture is stirred for a further 4 h at 70°C. After cooling it is filtered through silica gel, washed with DCM/MeOH, the filtrate obtained is dried using the rotary evaporator and A-1a is obtained.

    d) Method for synthesizing A-1b:



    [0124] 



    [0125] E-1a (2.0 g, 11.04 mmol) is taken up in DCM (40 mL) and mixed with TEA (5.1 mL, 27.6 mmol) and HATU (6.3 g, 16.6 mmol). After 10 min aniline E-2b (3.41 g, 11.04 mmol) is added and the mixture is stirred for another 2 h at RT. For working up it is diluted with water and the phases are separated. The organic phase is extracted 1 x with saturated NH4Cl solution, 1 x with saturated NaHCO3 solution and 1 x with saturated NaCl solution, dried on MgSO4, filtered, evaporated down using the rotary evaporator and Z-1b is obtained.

    [0126] The aromatic nitro compound Z-1b (3.5 g, 8.04 mmol) is taken up in EtOH (30 mL), combined with an ammonium chloride solution (215 mg, 4.02 mmol in 20 mL H2O) and heated to 70°C. At this temperature iron powder (4.49 g, 80.4 mmol) is added batchwise and the mixture is stirred for a further 5 h at 70°C. After cooling it is filtered through silica gel, washed with DCM/MeOH (9:1), the filtrate obtained is dried using the rotary evaporator and A-1b is obtained.

    [0127] Analogously to the method for synthesising A-1a and A-1b further anilines A-1 may be obtained from the corresponding educts E-1 and E-2.

    e) Method for synthesizing Z-2a:



    [0128] 



    [0129] P-2a (200 mg, 0.93 mmol), aniline A-1a (300 mg, 0.93 mmol) and TEA (155 µL, 1.53 mmol) are placed in DMF (3 mL). The reaction mixture is stirred overnight at 65 °C. The reaction mixture is combined with 20 mL water and stirred for 15 min. The precipitate formed is filtered off, washed with diethyl ether, taken up in toluene, evaporated down and Z-2a is obtained.

    f) Method for synthesising Z-2b:



    [0130] 



    [0131] P-2a (200 mg, 0.93 mmol) and aniline A-1c (291 mg, 0.93 mmol) are taken up in dioxane (3 mL). Hydrogen chloride (1M in Et2O, 5 µL, 0.102 mmol) is added. The reaction mixture is stirred for 25 min at 65°C in the microwave reactor. The precipitate formed is filtered off, washed with water, taken up in toluene, evaporated down and Z-2b is obtained.

    [0132] Analogously to the methods for synthesising Z-2a and Z-2b further intermediate compounds Z-2 are obtained by reacting components A-1 with P-2a.

    g) Method for synthesising example compound I-1:



    [0133] 



    [0134] Z-2a (50 mg, 0.1 mmol) and N-methylpiperazine E-3a (40 mg, 0.4 mmol) are taken up in 0.5 mL DMSO and DIPEA (180 µL, 1.4 mmol) is added. The reaction mixture is stirred for 25 min at 120 °C in the microwave reactor. The reaction mixture is filtered and purified by preparative HPLC. The product-containing fractions of I-1 (HPLC-MS: tRet. = 2.17 min; MS (M+H)+ = 568) are freeze-dried.

    h) Method for synthesizing Z-3a:



    [0135] 



    [0136] P-2a (1.439 g, 6.6 mmol) and aniline A-2a (1.0 g, 6.05 mmol) are placed in THF (5 mL). The reaction mixture is stirred overnight at RT. The precipitate formed is filtered off, dried and Z-3a is obtained.

    [0137] Analogously to the method for synthesising Z-3a further intermediate compounds Z-3 are obtained by reacting components A-2 with P-2a.

    i) Method for synthesising Z-4a:



    [0138] 



    [0139] Ester Z-3a (1.3 g, 3.77 mmol) is taken up in 25 mL DMSO with DIPEA (2.979 mL, 17.4 mmol) and N-methylpiperazine E-3a (0.443 mL, 4.351 mmol) is added. The reaction mixture is stirred for 20 min at 120 °C in the microwave reactor. The reaction mixture is mixed with water, the precipitate formed is filtered off, taken up in toluene, evaporated down 2 x azeotropically and Z-4a is obtained.

    [0140] Analogously to the method for synthesising Z-4a further intermediate compounds Z-4 are obtained by reacting intermediate compounds Z-3 with components E-3.

    j) Method for synthesising example compound I-2:



    [0141] 



    [0142] Methylester Z-4a (1.216 g, 2.98 mmol) is placed in MeOH (30 mL) and mixed at RT with an aqueous NaOH solution (5.0 mol/L, 12.146 mL, 60.73 mmol). Then the mixture is stirred overnight at 50°C. For working up the pH is adjusted to neutral by the addition of an HCl solution. The reaction mixture is extracted 2 x with water/EE (1:1), the organic phases are dried on MgSO4, filtered, evaporated down and Z-5a is obtained.

    [0143] Benzoic acid Z-5a (100 mg, 0.25 mmol) is taken up in DCM (5 mL) and mixed under argon with thionyl chloride (300 µL, 2.38 mmol). The reaction mixture is stirred for 1 h at RT. Then the mixture is evaporated down, dried azeotropically with dry toluene and Z-6a is obtained.

    [0144] Acid chloride Z-6a (100 mg, 0.24 mmol) is taken up in DCM (3 mL) and mixed with 3-bromo-5-trifluoromethyl-phenylamine E-2c (58 mg, 0.24 mmol) and pyridine (100 µL). The reaction mixture is stirred for 2 h at RT. For working up the mixture is evaporated down, taken up in DMSO, filtered and purified by preparative HPLC. The product-containing fractions of I-2 (HPLC-MS: tRet. = 2.44 min; MS (M+H)+ = 616/618) are freeze-dried.

    [0145] Analogously to methods a) to g) (synthesis route 1) or a), b) and h) to j) (synthesis route 2) besides I-1 and I-2 the following compounds I-3 to I-88 according to the invention are also prepared (Table 1).
    Table 1


    #StructuretRet. (HPLC) [min]MS (M+H)+
    I-1

    2.17 568
    I-2

    2.44 616/618
    I-3

    1.70 552
    I-4

    1.68 524
    I-5

    1.67 538
    I-6

    1.67 526
    I-7

    1.47 621
    I-8

    1.51 635
    I-9

    2.14 517
    I-10

    2.16 600
    I-11

    2.22 531
    I-12

    1.94 599
    I-13

    1.88 613
    I-14

    1.98 530
    I-15

    2.18 651
    I-16

    2.36 665
    I-17

    2.23 582
    I-18

    1.91 516
    I-19

    2.11 524
    I-20

    2.23 538
    I-21

    2.27 607
    I-22

    2.29 621
    I-23

    2.31 558
    I-24

    2.38 572
    I-25

    2.44 641
    I-26

    2.41 602/604
    I-27

    2.51 616/618
    I-28

    2.44 685/687
    I-29

    2.75 699/701
    I-30

    2.28 554
    I-31

    2.31 568
    I-32

    2.35 637
    I-33

    2.45 651
    I-34

    2.04 542
    I-35

    1.93 530
    I-36

    1.89 528
    I-37

    2.38 558
    I-38

    2.06 586
    I-39

    2.23 570
    I-40

    2.10 613
    I-41

    1.98 560
    I-42

    2.16 542
    I-43

    2.12 556
    I-44

    2.26 613
    I-45

    2.15 615
    I-46

    2.46 544
    I-47

    2.51 584
    I-48

    2.30 544
    I-49

    2.29 586
    I-50

    2.48 614
    I-51

    2.42 570
    I-52

    2.18 599
    I-53

    2.48 556
    I-54

    2.28 568
    I-55

    1.67 538
    I-56

    1.45 621
    I-57

    1.76 592
    I-58

    1.73 578
    I-59

    1.69 538
    I-60

    1.46 615
    I-61

    0.0 635
    I-62

    1.70 552
    I-63

    2.47 616
    I-64

    1.71 566
    I-65

    1.66 550
    I-66

    1.66 524
    I-67

    1.82 615
    I-68

    1.70 552
    I-69

    1.78 514
    I-70

    2.38 639
    I-71

    2.23 563
    I-72

    1.98 530
    I-73

    2.17 539
    I-74

    2.36 572
    I-75

    2.15 618
    I-76

    2.32 625
    I-77

    2.32 637
    I-78

    2.43 583
    I-79

    2.44 595
    I-80

    2.31 526
    I-81

    2.39 652
    I-82

    2.23 520
    I-83

    2.66 562
    I-84

    2.47 572
    I-85

    2.11 556
    I-86

    2.42 627
    I-87

    2.56 621
    I-88

    2.42 639



    Example compounds of type II:



    [0146] Example compounds II differ from those of type I by an inverted amide bond between the central (hetero-)aromatic six-membered ring and the group R2 (Reaction scheme B). These compounds are obtained analogously to the compounds I in terms of the method used, except that the reactivities are inverted accordingly in the educt components E-4 and E-5 or A-4 (compared with E-1 and E-2 or A-2).

    [0147] For compounds of type II for example the following two synthesis routes are possible: Starting from P-2a the 8-position is substituted by the aniline components A-3 or A-4.

    [0148] With regard to the use of A-3 reference is made to the remarks relating to Reaction scheme A (synthesis route 1 via intermediate compound Z-2). The components A-3 are obtained by amide coupling of the nitroanilines E-4 with carboxylic acids E-5 to obtain intermediate product Z-7 and subsequent reduction of the nitro group.

    [0149] When A-4 is used first of all only the central phenyl or heteroaryl ring and the precursor of a linker fragment (nitro → amino) of the later linker L2 is incorporated before the group R1 is introduced analogously. In this case additional reaction steps are necessary (reduction, activation, amidation) in order to obtain compounds II.

    [0150] Both the group R1 and the group R2 of compounds II according to the invention may be modified in other reaction steps (not shown), to obtain further compounds II according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

    a) Method for synthesizing A-3a:



    [0151] 



    [0152] 3-trifluoromethylbenzoic acid E-5a (10.03 g, 51.7 mmol) is taken up in 150 mL toluene. a solution of oxalyl chloride (7.6 mL, 57.58 mmol) in 100 mL toluene is added dropwise. DMF (4 mL) is added and the reaction mixture is stirred for 2 h at 90 °C. Then it is evaporated down, the residue is taken up in 100 mL DCM and cooled with an ice bath. 4-Methyl-3-nitroaniline E-4a (8.91 g, 56.8 mmol) and TEA (8.7 mL, 62.14 mmol) are added, the ice bath is removed and the reaction mixture is stirred overnight at RT. For working up it is filtered, washed with DCM and the filtrate is evaporated down. The residue is mixed with 0.5 M NaOH solution (20 mL), the precipitate formed is filtered off and washed with water. The solid is suspended in 20 mL 0.5 M HCl solution and 10 mL EE, stirred for 15 min at RT and filtered off. The solid is suspended in 30 mL TBME, stirred for 10 min in the ultrasound bath, filtered off, dried and Z-7a (HPLC-MS: tRet. = 2.30 min; MS (M+H)+ = 325) is obtained.

    [0153] The aromatic nitro compound Z-7a (4.4 g, 13.57 mmol) is taken up in THF (85 mL) and MeOH (15 mL). Pd/C (200 mg) is carefully added. The reaction vessel is filled with 7 bar H2, the reaction mixture is stirred overnight at RT, filtered through Celite, washed with THF, the filtrate obtained is dried using the rotary evaporator and A-3a (HPLC-MS: tRet. = 1.73 min; MS (M+H)+ = 295) is obtained.

    [0154] Analogously to the method for synthesising A-3a further anilines A-3 were obtained from the corresponding educts E-4 and E-5.

    b) Method for synthesizing Z-8a:



    [0155] 



    [0156] P-2a (975 mg, 4.51 mmol) is taken up in DMF (25 mL) and TEA (754 µL, 5.41 mmol) is added. The reaction mixture is combined with aniline A-3a (1.327 g, 4.51 mmol) and stirred overnight at RT. For working up 100 mL ice water are added, the precipitate formed is filtered off and Z-8a is obtained.

    [0157] Analogously to the method for synthesising Z-8a further intermediate compounds Z-8 are obtained by reacting components A-3 with P-2a.

    c) Method for synthesising example compound II-1:



    [0158] 



    [0159] Z-8a (50 mg, 0.11 mmol) is taken up in DMSO (900 µL), mixed with N-methylpiperazine E-3a (32 mg, 0.32 mmol) and stirred for 15 min at 150°C in the microwave reactor. The reaction mixture is purified by preparative HPLC. The product-containing fractions of II-1 (HPLC-MS: tRet. = 1.59 min; MS (M+H)+ = 538) are freeze-dried.

    [0160] Analogously to methods a) to c) (synthesis route 1) or synthesis route 2 described, in addition to II-1 the following compounds II-2 to II- 19 according to the invention are also prepared (Table 2).
    Table 2


    #StructuretRet. (HPLC) [min]MS (M+H)+
    II-1

    1.59 538
    II-2

    1.63 552
    II-3

    1.73 553
    II-4

    1.66 546
    II-5

    1.80 546
    II-6

    1.80 546
    II-7

    2.29 483
    II-8

    1.42 621
    II-9

    1.75 592
    II-10

    1.69 578
    II-11

    1.64 538
    II-12

    1.74 615
    II-13

    1.68 552
    II-14

    0.0 635
    II-15

    1.64 552
    II-16

    2.40 616
    II-17

    1.68 566
    II-18

    1.61 550
    II-19

    1.62 524



    Example compounds of type III:



    [0161] 2,8-disubstituted pyrimidopyrimidines III may also be obtained for example by the following methods (Reaction scheme C, synthesis routes 1-3).

    [0162] Starting from 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a the 8-position is substituted by the aniline components A-1 or A-2, preferably under basically catalysed conditions at elevated temperature.

    [0163] If A-1 is used (synthesis route 1) the complete left-hand molecular part of the end compounds III is thereby introduced into the intermediate compound Z-12, so that finally there only remains the substitution in the 2-position by components R1-H (E-3), which are preferably primary and secondary (also cyclic) amines or alcohols (in the form of the alkoxides). For this, however, first the methylsulphanyl group has to be activated in the 2-position by oxidation to form the corresponding sulphoxide/sulphone for the substitution (for the synthesis of the components A-1 cf. the remarks made under Reaction scheme A). In this reaction, a mixture of the sulphoxide and sulphone is usually obtained, which is further reacted as one.

    [0164] By contrast, by using A-2 (synthesis routes 2 and 3) first of all only the central phenyl or heteroaryl ring and a protected linker fragment (carboxylate) of the later linker L2 (e.g. amide) is incorporated , before the group R1 is introduced. With the intermediate compound Z-14 there are the alternative possibilities of either oxidising/activating the methylsulphanyl group, then substituting it with a component E-3 and lastly, after saponification, introducing the group R2 (through the component E-2) (synthesis route 2) or first of all carrying out saponification and oxidation and then carrying out the nucleophilic substitution by E-3 followed by the amide coupling of E-2 (synthesis route 3). Alternatively to P-3a other educts P-3 are possible which allow successive and selective substitution, i.e. have other leaving groups.

    [0165] Both the group R1 and the group R2 of compounds III according to the invention may be modified in other reaction steps (not shown), to obtain other compounds III according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

    a) Method for synthesising P-3a:



    [0166] 



    [0167] 8-hydroxy-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine (16.5 g, 85 mmol) is placed in acetonitrile (125 mL), combined with DMF (400 µL) and heated to 30°C. At this temperature the thionyl chloride (16 mL, 215 mmol) is added dropwise. The reaction mixture is stirred for 4.5 h at 95 °C. After cooling it is evaporated down, the residue is taken up in DCM and filtered through silica gel. The filtrate is washed with a saturated NaHCO3 solution, dried on Na2SO4, filtered off, the solvent removed and P-3a (HPLC-MS: tRet. = 1.64 min; MS (M+H)+ = 213/215) is obtained.

    b) Method for synthesizing Z-12a:



    [0168] 



    [0169] Aniline A-1a (453 mg, 1.4 mmol) and 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (270 mg, 1.27 mmol) are placed in dioxane (3 mL) and DIPEA (352 µL, 1.9 mmol) and refluxed overnight. For working up the reaction mixture is evaporated down, the residue is suspended in MeOH, the precipitate formed is filtered off, dried and Z-12a (HPLC-MS: tRet. = 1.99 min; MS (M+H)+ = 501) is obtained.

    c) Method for synthesising Z-12b:



    [0170] 



    [0171] Aniline A-1b (3.3 g, 8.14 mmol) and 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (1.73 g, 8.14 mmol) are placed in acetic acid (20 mL) and stirred overnight at 50 °C. For working up the reaction mixture is evaporated down, the residue is suspended in isopropanol/water (1:1), the precipitate formed is filtered off, dried and Z-12b is obtained.

    [0172] Analogously to the methods for synthesising Z-12a and Z-12b further intermediate compounds Z-12 are obtained by reacting components A-1 with P-3a.

    d) Method for synthesising example compound III-1:



    [0173] 



    [0174] Z-12a (310 mg, 0.62 mmol) is taken up in DCM (5 mL). Then at RT mCPBA (70 %, 183 mg, 0.74 mmol) is added and the reaction mixture is stirred for 1 h at RT. The precipitate formed is filtered off, washed with DCM, dried and Z-13a is obtained. Sulphoxide/sulphone Z-13a (90 mg, 0.174 mmol) and N-methylpiperazine E-3a (31 µL, 0.28 mmol) are placed in dioxane (0.5 mL). TEA (51 µL, 0.35 mmol) is added dropwise. The reaction mixture is stirred for 2 h at 60 °C. For working up the mixture is evaporated down, the residue is suspended in isopropanol/water and filtered off. The solid is washed with water, dissolved in acetonitrile/water/2 M HCl solution, freeze-dried and III-1 (HPLC-MS: tRet. = 2.18 min; MS (M+H)+ = 553) is obtained.

    e) Method for synthesizing Z-14a:



    [0175] 



    [0176] Methyl 3-amino-4-methylbenzoate A-2a (4.04 g, 24.45 mmol) and 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (80 %, 5.0 g, 18.81 mmol) are placed in dioxane (8 mL) and DIPEA (4.525 mL, 24.45 mmol) and refluxed overnight with stirring. For working up the reaction mixture is evaporated down, the residue is suspended in MeOH, the precipitate formed is filtered off, dried and Z-14a (HPLC-MS: tRet. = 2.01 min; MS (M+H)+ = 342) is obtained.

    [0177] Analogously to the method for synthesising Z-14a further intermediate compounds Z-14 are obtained by reacting components A-2 with P-3a.

    f) Method for synthesising Z-16a:



    [0178] 



    [0179] Z-14a (5.5 g, 16.1 mmol) is taken up in DCM (40 mL), combined at RT with mCPBA (70 %, 3.61 g, 16.1 mmol) and stirred for 1 h. The precipitate formed is filtered off, washed with DCM, dried and Z-15a (HPLC-MS: tRet. = 1.45 min; MS (M+H(+Na))+ = 358(380)) is obtained.

    [0180] Sulphoxide/sulphone Z-15a (1.0 g, 2.8 mmol) and morpholine E-3b (704 µL, 7.28 mmol) are placed in dioxane (30 mL). TEA (815 µL, 5.6 mmol) is added dropwise to this suspension and then it is heated to 60 °C for 2 h. For working up the mixture is evaporated down, the residue is suspended with iPrOH/water, filtered, dried and Z-16a (HPLC-MS: tRet. = 1.94 min; MS (M+H)+ = 381) is obtained.

    g) Method for synthesizing Z-16b:



    [0181] 



    [0182] Z-14a (5.5 g, 16.1 mmol) is taken up in DCM (40 mL), combined at RT with mCPBA (70 %, 3.61 g, 16.1 mmol) and stirred for 1 h. The precipitate formed is filtered off, washed with DCM, dried and Z-15a (HPLC-MS: tRet. = 1.45 min; MS (M+H(+Na))+ = 358(380)) is obtained.

    [0183] Sulphoxide/sulphone Z-15a (3.0 g, 8.4 mmol) and 1-(2-methoxyethyl)-piperazine E-3c (2.5 mL, 16.8 mmol) are placed in dioxane (25 mL). TEA (3 mL, 23 mmol) is added dropwise to this suspension and then the mixture is heated to 60 °C for 2 h. For working up the mixture is evaporated down, the residue is suspended with iPrOH/water, filtered, dried and Z-16b (HPLC-MS: tRet. = 1.95 min; MS (M+H)+ = 438) is obtained.

    [0184] Analogously to the methods for synthesising Z-16a and Z-16b other intermediate compounds Z-16 are obtained by oxidising components Z-14 and reacting with amines E-3. Further intermediate compounds Z-16 are obtained by reacting with alcohols E-3 (in the form of their alkoxides), e.g. with sodium methoxide.

    h) Method for synthesising example compound III-2:



    [0185] 



    [0186] Z-16a (1.0 g, 2.63 mmol) is placed in THF (15 mL) and combined at RT with an aqueous LiOH solution (1 M, 10.5 mL). Then the mixture is refluxed for 2 h with stirring. For working up the pH is adjusted to 5.5 by the addition of a 1N HCl solution. After evaporation in vacuo the precipitate formed is filtered off, washed with water, dried and Z-17a (HPLC-MS: tRet. = 1.31 min; MS (M+H)+ = 367) is obtained.

    [0187] Benzoic acid Z-17a (1.1 g, 3.0 mmol) is suspended in thionyl chloride and stirred for 1 h at 60°C. The reaction mixture is evaporated down and dried azeotropically with dry toluene. The acid chloride Z-18a (400 mg, 1.04 mmol) is then taken up in a little NMP (1.2 mL) and combined with 4-methoxy-3-trifluoromethyl-phenylamine E-2a (188 mg, 1.55 mmol) and DIPEA (300 µL, 1.75 mmol). For working up water is added, the precipitate obtained is filtered off, dried and Example compound III-2 (HPLC-MS: tRet. = 2.20 min; MS (M+H)+ = 540) is obtained.

    i) Method for synthesizing Z-17b:



    [0188] 



    [0189] Z-16b (3.42 g, 7.81 mmol) is placed in THF (25 mL) and combined at RT with an aqueous LiOH solution (1.3 g, 31.4 mmol in 10 mL). Then the mixture is refluxed for 2 h with stirring. For working up the pH is adjusted to 5.5 by the addition of a 1N HCl solution. After evaporation in vacuo the precipitate formed is filtered off, washed with 5 mL water, dried and Z-17b (HPLC-MS: tRet. = 1.05 min; MS (M+H)+ = 424) is obtained.

    j) Method for synthesising Z-20a:



    [0190] 



    [0191] Z-14a (880 mg, 2.58 mmol) is placed in THF (30 mL) and 1M NaOH solution (3.87 mL, 3.87 mmol) is added. The reaction mixture is stirred for 3 h at 50 °C and then overnight at RT. For working up it is concentrated by rotary evaporation, the residue is acidified slightly with dilute HCl solution, the precipitate formed is suction filtered and washed with water. The intermediate product Z-19a (HPLC-MS: tRet. = 0.83 min; MS (M+H)+ = 328) is triturated with a little EtOH, suction filtered and dried.

    [0192] Benzoic acid Z-19a (29.0 g, 88.59 mmol) is placed in glacial acetic acid (800 mL) and sodium periodate (19.139 g, 88.59 mmol) is added. The reaction mixture is heated for 3 h to 80 °C. After cooling it is mixed with aqueous Na2S2O5 solution (15 mL; 10 %) and largely concentrated by rotary evaporation. The residue is mixed with water, the precipitate formed is suction filtered, washed with water, dried in the vacuum dryer at 70°C and Z-20a (HPLC-MS: tRet. = 1.81 min; MS (M+H)+ = 360) is obtained.

    [0193] Analogously to the method for synthesising Z-20a further intermediate compounds Z-20 are obtained by saponification of components Z-14 and oxidation.

    k) Method for synthesising example compound III-3:



    [0194] 



    [0195] Sulphoxide/sulphone Z-20a (2.0 g, 5.57 mmol), amine E-3d (1.137 g, 11.13 mmol) and DIPEA (1.94 mL, 11.03 mmol) are taken up in DMF (30 mL) and stirred overnight at RT. The solvent is spun off, the residue is mixed with a little water. The precipitate formed is suction filtered, washed with a little cold water, dried and Z-17a (HPLC-MS: tRet. = 1.47 min; MS (M+H)+ = 382) is obtained.

    [0196] Benzoic acid Z-17a (50 mg, 0.13 mmol) is suspended in DCM (5 mL). 1-Chloro-N,N,2-trimethylpropenylamine (41 mg, 0.30 mmol) is added and the reaction mixture is stirred for 3 h at RT. Then it is concentrated by rotary evaporation and the residue is suspended in dioxane/acetonitrile (3 mL, 1:1). Benzylamine E-2c (100 mg, 0.50 mmol) and DIPEA (65 mg, 0.50 mmol) are added and the reaction mixture is stirred overnight at RT. For working up the mixture is concentrated by rotary evaporation, the residue is taken up in DMF and the reaction mixture is purified by RP-LC/MS. The product-containing fractions of III-3 (HPLC-MS: tRet. = 1.91 min; MS (M+H)+ = 525) are freeze-dried.

    [0197] Analogously to the methods a) to d) (synthesis route 1) or a), e) to h) (synthesis route 2) as well as a), d), i) and k) (synthesis route 3), besides III-1, III-2 and III-3 the following compounds III-4 to III-608 according to the invention are also prepared (Table 3).
    Table 3


    #StructuretRet. (HPLC) [min]MS (M+H)+
    III-1

    2.18 553
    III-2

    2.21 540
    III-3

    1.91 527
    III-4

    2.27 562
    III-5

    1.74 575
    III-6

    2.56 572
    III-7

    1.73 587
    III-8

    1.75 601
    III-9

    1.73 573
    III-10

    2.46 558
    III-11

    1.72 617
    III-12

    2.26 560
    III-13

    2.41 544
    III-14

    1.69 561
    III-15

    1.73 603
    III-16

    2.27 518
    III-17

    2.08 558
    III-18

    1.65 571
    III-19

    2.33 568
    III-20

    1.64 583
    III-21

    1.77 597
    III-22

    1.64 569
    III-23

    2.35 554
    III-24

    1.63 613
    III-25

    2.29 556
    III-26

    2.09 540
    III-27

    2.34 557
    III-28

    1.63 599
    III-29

    2.74 514
    III-30

    2.07 546
    III-31

    2.32 559
    III-32

    2.32 556
    III-33

    2.33 585
    III-34

    1.65 557
    III-35

    2.82 542
    III-36

    1.64 601
    III-37

    2.69 544
    III-38

    2.16 528
    III-39

    2.27 545
    III-40

    1.64 587
    III-41

    2.80 502
    III-42

    2.29 596
    III-43

    2.41 609
    III-44

    2.57 606
    III-45

    2.41 621
    III-46

    1.78 635
    III-47

    2.44 607
    III-48

    2.72 592
    III-49

    2.40 651
    III-50

    2.24 594
    III-51

    2.38 578
    III-52

    1.70 595
    III-53

    2.46 637
    III-54

    2.30 552
    III-55

    2.29 545
    III-56

    1.73 558
    III-57

    2.61 555
    III-58

    1.72 570
    III-59

    2.56 584
    III-60

    1.70 556
    III-61

    2.51 541
    III-62

    1.70 600
    III-63

    2.26 543
    III-64

    2.43 527
    III-65

    2.53 544
    III-66

    1.69 586
    III-67

    2.57 511
    III-68

    2.92 521
    III-69

    2.59 467
    III-70

    1.57 536
    III-71

    1.62 550
    III-72

    1.53 522
    III-73

    2.25 507
    III-74

    1.54 566
    III-75

    1.99 509
    III-76

    1.99 493
    III-77

    1.52 510
    III-78

    1.53 552
    III-79

    1.94 524
    III-80

    1.81 507
    III-81

    1.80 505
    III-82

    1.89 489
    III-83

    1.82 463
    III-84

    2.37 495
    III-85

    2.66 505
    III-86

    1.84 520
    III-87

    2.08 517
    III-88

    2.50 491
    III-89

    2.32 493
    III-90

    2.43 477
    III-91

    1.78 494
    111-92

    1.79 536
    III-93

    2.36 451
    111-94

    2.15 437
    III-95

    2.38 518
    III-96

    2.46 532
    III-97

    1.54 546
    III-98

    1.53 298 (M+2H)2+
    III-99

    1.63 305 (M+2H)2+
    III-100

    1.55 282 (M+2H)2+
    III-101

    1.48 285 (M+2H)2+
    III-102

    1.67 314 (M+2H)2+
    III-103

    1.62 305 (M+2H)2+
    III-104

    1.47 304 (M+2H)2+
    III-105

    1.65 307 (M+2H)2+
    III-106

    1.68 296 (M+2H)2+
    III-107

    1.31 307 (M+2H)2+
    III-108

    1.52 297 (M+2H)2+
    III-109

    1.59 289 (M+2H)2+
    III-110

    1.46 291 (M+2H)2+
    III-111

    1.54 282 (M+2H)2+
    III-112

    1.64 290 (M+2H)2+
    III-113

    1.32 307 (M+2H)2+
    III-114

    1.31  
    III-115

    1.54 276 (M+2H)2+
    III-116

    1.44 269 (M+2H)2+
    III-117

    1.67 290 (M+2H)2+
    III-118

    1.70 314 (M+2H)2+
    III-119

    1.51 306 (M+2H)2+
    III-120

    1.72 311 (M+2H)2+
    III-121

    1.62 313 (M+2H)2+
    III-122

    1.50 290 (M+2H)2+
    III-123

    1.45 293 (M+2H)2+
    III-124

    1.67 322 (M+2H)2+
    III-125

    1.60 313 (M+2H)2+
    III-126

    1.44 312 (M+2H)2+
    III-127

    1.64 315 (M+2H)2+
    III-128

    1.67 304 (M+2H)2+
    III-129

    1.28 316 (M+2H)2+
    III-130

    1.95 610
    III-131

    1.59 297 (M+2H)2+
    III-132

    1.43 299 (M+2H)2+
    III-133

    1.51 290 (M+2H)2+
    III-134

    1.63 298 (M+2H)2+
    III-135

    1.29 316 (M+2H)2+
    III-136

    1.27 316 (M+2H)2+
    III-137

    1.50 284 (M+2H)2+
    III-138

    1.41 277 (M+2H)2+
    III-139

    1.65 298 (M+2H)2+
    III-140

    1.67 322 (M+2H)2+
    III-141

    1.53 300 (M+2H)2+
    III-142

    1.62  
    III-143

    1.53  
    III-144

    1.47 287 (M+2H)2+
    III-145

    1.61 307 (M+2H)2+
    III-146

    1.47 306 (M+2H)2+
    III-147

    1.64 309 (M+2H)2+
    III-148

    1.31 309 (M+2H)2+
    III-149

    1.50 299 (M+2H)2+
    III-150

    1.59 291 (M+2H)2+
    III-151

    1.46 293 (M+2H)2+
    III-152

    1.53  
    III-153

    1.63 292 (M+2H)2+
    III-154

    1.32 309 (M+2H)2+
    III-155

    1.52 278 (M+2H)2+
    III-156

    1.44  
    III-157

    1.67 292 (M+2H)2+
    III-158

    1.76 311 (M+2H)2+
    III-159

    1.65 313 (M+2H)2+
    III-160

    1.55 290 (M+2H)2+
    III-161

    1.41 321 (M+2H)2+
    III-162

    1.51 293 (M+2H)2+
    III-163

    1.70 322 (M+2H)2+
    III-164

    1.64 313 (M+2H)2+
    III-165

    1.50 312 (M+2H)2+
    III-166

    1.67 315 (M+2H)2+
    III-167

    1.72 304 (M+2H)2+
    III-168

    1.34 316 (M+2H)2+
    III-169

    1.49 299 (M+2H)2+
    III-170

    1.56 290 (M+2H)2+
    III-171

    1.66 298 (M+2H)2+
    III-172

    1.36 316 (M+2H)2+
    III-173

    1.34 316 (M+2H)2+
    III-174

    1.55 284 (M+2H)2+
    III-175

    1.47 277 (M+2H)2+
    III-176

    1.69 298 (M+2H)2+
    III-177

    1.72 322 (M+2H)2+
    III-178

    1.61 352 (M+2H)2+
    III-179

    1.28 477
    III-180

    1.54 536
    III-181

    1.57 648
    III-182

    1.57 551
    III-183

    1.47 475
    III-184

    1.46 469
    III-185

    1.28 433
    III-186

    1.31 318 (M+2H)2+
    III-187

    1.26 463
    III-188

    1.57 537
    III-189

    1.46 461
    III-190

    1.46 455
    III-191

    1.27 419
    III-192

    1.48 311 (M+2H)2+
    III-193

    1.48 450
    III-194

    1.51 406
    III-195

    1.50 564
    III-196

    1.33 637
    III-197

    1.28 465
    III-198

    1.55 524
    III-199

    1.58 636
    III-200

    1.57 539
    III-201

    1.48 463
    III-202

    1.47 457
    III-203

    1.29 421
    III-204

    1.52 312 (M+2H)2+
    III-205

    1.54 452
    III-206

    1.88 511
    III-207

    1.89 526
    III-208

    1.79 450
    III-209

    1.79 444
    III-210

    1.57 408
    III-211

    1.61 310 (M+2H)2+
    III-212

    1.67 448
    III-213

    2.00 507
    III-214

    2.00 522
    III-215

    1.92 446
    III-216

    1.64 555
    III-217

    1.61 537
    III-218

    1.65 539
    III-219

    1.64 567
    III-220

    1.69 571
    III-221

    1.57 551
    III-222

    1.64 553
    III-223

    1.26 256 (M+2H)2+
    III-224

    1.66 525
    III-225

    1.69 555
    III-226

    1.65 525
    III-227

    1.57 537
    III-228

    1.25 249 (M+2H)2+
    III-229

    1.67 511
    III-230

    1.69 541
    III-231

    1.65 543
    III-232

    1.62 525
    III-233

    1.66 527
    III-234

    1.65 555
    III-235

    1.71 559
    III-236

    1.58 539
    III-237

    1.65 541
    III-238

    1.27 500
    III-239

    1.68 513
    III-240

    1.70 543
    III-241

    2.00 514
    III-242

    1.90 526
    III-243

    1.47 244 (M+2H)2+
    III-244

    2.04 500
    III-245

    2.12 510
    III-246

    2.01 522
    III-247

    1.58 242 (M+2H)2+
    III-248

    2.16 496
    III-249

    2.26 526
    III-250

    1.93 508
    III-251

    1.49 576
    III-252

    1.32 325 (M+2H)2+
    III-253

    1.92 440
    III-254

    1.71 404
    III-255

    1.55 303 (M+2H)2+
    III-256

    1.58 434
    III-257

    2.04 508
    III-258

    1.94 432
    III-259

    1.95 426
    III-260

    1.72 390
    III-261

    1.81 524
    III-262

    2.40 538
    III-263

    1.12 484
    III-264

    2.13 502
    III-265

    2.17 512
    III-266

    2.14 494
    III-267

    2.16 496
    III-268

    2.22 524
    III-269

    2.24 528
    III-270

    2.17 510
    III-271

    1.68 469
    III-272

    2.20 482
    III-273

    2.16 519
    III-274

    1.95 533
    III-275

    2.10 495
    III-276

    2.03 493
    III-277

    2.08 605
    III-278

    2.15 496
    III-279

    1.50 526
    III-280

    1.79 533
    III-281

    1.76 550
    III-282

    1.82 545
    III-283

    1.75 538
    III-284

    1.80 562
    III-285

    1.80 520
    III-286

    1.87 530
    III-287

    1.82 512
    III-288

    1.92 542
    III-289

    1.95 546
    III-290

    1.88 528
    III-291

    2.02 530
    III-292

    1.85 537
    III-293

    1.67 551
    III-294

    1.88 498
    III-295

    2.10 623
    III-296

    1.46 531
    III-297

    1.55 541
    III-298

    1.53 523
    III-299

    1.56 553
    III-300

    1.62 557
    III-301

    1.56 539
    III-302

    1.85 512
    III-303

    1.37 562
    III-304

    1.87 540
    III-305

    1.45 522
    III-306

    1.97 528
    III-307

    1.72 524
    III-308

    2.38 510
    III-309

    1.32 485
    III-310

    1.82 525
    III-311

    1.53 548
    III-312

    1.48 634
    III-313

    1.97 518
    III-314

    2.16 528
    III-315

    1.80 510
    III-316

    1.87 508
    III-317

    1.86 534
    III-318

    1.80 506
    III-319

    1.86 550
    III-320

    1.61 549
    III-321

    1.75 511
    III-322

    1.69 509
    III-323

    1.86 621
    III-324

    1.72 524
    III-325

    1.60 448
    III-326

    1.59 442
    III-327

    2.14 512/513
    III-328

    2.03 516
    III-329

    2.06 526
    III-330

    2.03 508
    III-331

    2.13 542
    III-332

    2.06 524
    III-333

    2.05 533
    III-334

    1.87 547
    III-335

    2.00 509
    III-336

    2.40 539
    III-337

    1.90 544
    III-338

    1.97 619
    III-339

    2.41 509
    III-340

    1.88 535
    III-341

    2.31 497
    III-342

    1.48 517
    III-343

    1.87 527
    III-344

    1.63 548
    III-345

    2.23 513
    III-346

    1.54 408
    III-347

    2.11 540
    III-348

    1.91 502
    III-349

    2.15 510
    III-350

    2.24 498
    III-351

    2.20 622
    III-352

    2.03 516
    III-353

    1.86 488
    III-354

    2.14 488
    III-355

    2.09 511
    III-356

    2.26 540
    III-357

    2.08 489
    III-358

    2.09 477
    III-359

    2.16 503
    III-360

    2.35 517
    III-361

    2.16 517
    III-362

    2.42 517
    III-363

    2.13 503
    III-364

    2.07 489
    III-365

    2.23 503
    III-366

    2.27 495
    III-367

    2.07 484
    III-368

    2.37 517
    III-369

    2.22 503
    III-370

    2.08 601
    III-371

    2.24 500
    III-372

    2.06 516
    III-373

    2.00 529
    III-374

    2.43 540/542
    III-375

    2.21 556/558
    III-376

    2.19 522
    III-377

    2.36 506
    III-378

    2.14 535
    III-379

    2.17 549
    III-380

    1.54 440
    III-381

    2.02 493
    III-382

    2.20 612
    III-383

    2.20 513
    III-384

    1.73 506
    III-385

    2.04 630
    III-386

    1.81 513
    III-387

    1.65 506
    III-388

    1.86 612
    III-389

    1.93 630
    III-390

    1.86 544
    III-391

    1.73 492
    III-392

    1.63 492
    III-393

    2.02 515
    III-394

    2.27 603
    III-395

    1.96 550
    III-396

    2.15 534
    III-397

    2.18 546
    III-398

    2.03 520
    III-399

    1.96 520
    III-400

    2.15 520
    III-401

    2.02 534
    III-402

    1.97 601
    III-403

    2.14 585
    III-404

    2.17 597
    III-405

    2.04 571
    III-406

    2.06 521
    III-407

    2.60 652
    III-408

    2.58 664
    III-409

    2.49 582
    III-410

    1.83 526
    III-411

    2.28 542
    III-412

    2.24 491
    III-413

    2.66 650
    III-414

    2.26 612
    III-415

    2.80 638
    III-416

    2.64 608
    III-417

    2.25 620
    III-418

    2.20 598
    III-419

    2.48 650
    III-420

    2.45 599
    III-421

    2.00 559
    III-422

    2.45 585
    III-423

    2.25 567
    III-424

    2.29 679
    III-425

    1.96 545
    III-426

    2.18 568
    III-427

    2.20 597
    III-428

    2.50 518
    III-429

    2.18 522
    III-430

    2.28 529
    III-431

    1.85 565
    III-432

    2.04 623
    III-433

    2.13 579
    III-434

    2.03 595
    III-435

    2.01 581
    III-436

    1.91 567
    III-437

    2.10 581
    III-438

    2.38 612
    III-439

    2.37 624
    III-440

    2.49 594
    III-441

    2.29 622
    III-442

    2.33 610
    III-443

    2.24 567
    III-444

    2.68 595
    III-445

    2.38 524
    III-446

    1.98 515
    III-447

    2.42 543
    III-448

    1.93 501
    III-449

    2.72 566
    III-450

    2.34 610
    III-451

    2.54 656
    III-452

    2.36 628
    III-453

    2.53 613
    III-454

    2.26 592
    III-455

    2.76 652
    III-456

    2.40 638
    III-457

    2.30 610
    III-458

    2.33 624
    III-459

    2.46 595
    III-460

    2.69 650
    III-461

    2.41 636
    III-462

    2.21 608
    III-463

    2.25 622
    III-464

    2.49 542
    III-465

    2.10 504
    III-466

    2.54 530
    III-467

    2.35 512
    III-468

    2.39 500
    III-469

    2.40 612
    III-470

    2.37 624
    III-471

    2.04 490
    III-472

    2.24 513
    III-473

    2.31 542
    III-474

    2.27 491
    III-475

    2.70 582
    III-476

    2.23 544
    III-477

    2.83 570
    III-478

    2.48 552
    III-479

    2.65 540
    III-480

    2.45 531
    III-481

    2.38 599
    III-482

    2.28 572
    III-483

    2.39 599
    III-484

    2.27 528
    III-485

    2.49 570
    III-486

    2.16 585
    III-487

    2.03 475
    III-488

    1.99 600
    III-489

    1.80 572
    III-490

    2.09 556
    III-491

    1.92 516
    III-492

    2.04 530
    III-493

    2.05 528
     
    #StructuretRet. (HPLC) [min]MS (M+H)+
    III-494

    2.34 544
    III-495

    1.91 530
    III-496

    1.85 516
    III-497

    1.75 514
    #StructuretRet. (HPLC) [min]MS (M+H)+
    III-498

    2.04 732
    III-499

    2.21 488
    III-500

    2.54 484
    III-501

    2.26 683
    III-502

    2.16 647
    III-503

    2.28 626
    III-504

    2.13 502
    III-505

    1.87 678
    III-506

    2.17 626
    III-507

    2.07 590
    III-508

    2.04 490
    III-509

    2.47 736
    III-510

    2.41 621
    III-511

    2.35 628
    III-512

    2.13 508
    III-513

    1.99 502
    III-514

    2.36 612
    III-515

    1.95 488
    III-516

    2.18 489
    III-517

    2.16 546
    III-518

    2.30 598
    III-519

    2.42 497
    III-520

    2.32 495
    III-521

    2.36 509
    III-522

    2.38 531
    III-523

    2.09 623
    III-524

    1.99 622
    III-525

    1.97 595
    III-526

    1.80 638
    III-527

    1.86 608
    III-528

    2.26 627/629
    III-529

    1.92 639
    III-530

    1.86 576
    III-531

    1.89 592
    III-532

    1.96 592
    III-533

    2.11 601/603
    III-534

    2.08 652
    III-535

    2.01 597
    III-536

    1.99 585
    III-537

    1.89 634
    III-538

    2.18 633
    III-539

    2.28 623
    III-540

    2.13 611
    III-541

    2.38 625
    III-542

    2.21 613
    III-543

    2.11 568
    III-544

    1.92 568
    III-545

    2.17 568
    III-546

    1.91 554
    III-547

    2.15 526
    III-548

    2.00 554
    III-549

    1.86 535
    III-550

    2.14 568
    III-551

    2.00 554
    III-552

    1.84 652
    III-553

    2.24 650
    III-554

    2.20 650
    III-555

    2.12 593
    III-556

    2.27 621
    III-557

    1.98 636
    III-558

    1.93 623
    III-559

    2.11 651
    III-560

    2.20 607
    III-561

    2.02 567
    III-562

    2.22 654
    III-563

    1.98 571
    III-564

    2.07 571
    III-565*

    1.88 447
    III-566*

    2.37 473
    III-567*

    2.31 581
    III-568*

    2.15 455
    III-569*

    2.11 485
    III-570*

    2.25 443
    III-571*

    2.19 555
    III-572*

    2.28 538
    III-573*

    2.59 595
    III-574*

    2.21 567
    III-575*

    1.85 433
    III-576*

    2.11 553
    III-577*

    2.07 434
    III-578*

    2.08 456
    III-579*

    2.24 485
    III-580

    2.21 503
    III-581

    2.08 503
    III-582

    2.10 560
    III-583

    2.23 505
    III-584

    2.20 554
    III-585

    2.12 554
    III-586

    2.12 611
    III-587

    2.29 556
    III-588**

    1.98 516
    III-589**

    2.01 530
    III-590**

    1.96 518
    III-591**

    2.02 503
    III-592

    1.81 571
    III-593

    1.83 622
    III-594

    1.94 560
    III-595

    1.66 526
    III-596

    2.01 585
    III-597

    2.05 595
    III-598

    1.93 504
    III-599

    2.17 595
    III-600

    2.18 569
    III-601

    2.14 604
    III-602

    1.86 571
    III-603

    2.04 542
    III-604

    2.10 580
    III-605

    1.66 483
    III-606

    2.00 568
    III-607

    2.15 642
    III-608

    2.23 629
    * using NaOMe instead of amines (E-3)
    ** using phenols instead of anilines A-1



    Example compounds of type IV:



    [0198] Example compounds IV differ from those of type III by an inverted amide bond between the central (hetero-)aromatic six-membered ring and the group R2 (Reaction scheme D). These compounds are obtained analogously to the compounds III in terms of the method used, except that the reactivities are inverted accordingly in the educt components E-4 and E-5 (for the synthesis of A-3, cf. Reaction scheme B) or A-4 (compared with E-1 and E-2 or A-2, cf. Reaction schemes A and C).

    [0199] For the compound of type IV for example the following two synthesis routes are possible: Starting from P-3a the 8-position is substituted by the aniline components A-3 or A-4, preferably under basically catalysed conditions at elevated temperature.

    [0200] With regard to the use of A-3 (synthesis route 1) reference is made to the remarks relating to Reaction scheme C (synthesis route 1 via intermediate compound Z-12) (final substitution by E-3 after oxidative activation of the methylsulphanyl group; regarding the synthesis of components A-3 cf. the remarks under Reaction scheme B).

    [0201] When A-4 is used (synthesis routes 2 and 3) first of all only the central phenyl or heteroaryl ring and the precursor of a linker fragment (nitro → amino) of the later linker L2 is incorporated. With the intermediate compound Z-24 there are the alternative possibilities of either oxidising/activating the methylsulphanyl group, then substituting it with a component E-3 and lastly, after reduction, introducing the group R2 (via the component E-5) (synthesis route 2) or first of all carrying out reduction and amide coupling with E-5 and then after oxidative activation carrying out the nucleophilic substitution by E-3 (synthesis route 3).

    [0202] Both the group R1 and the group R2 of compounds IV according to the invention may be modified in other reaction steps (not shown), to obtain further compounds IV according to the invention. These reaction steps may be reactions of substitution, alkylation, acylation or addition.

    a) Method for synthesizing Z-24a:



    [0203] 



    [0204] 8-chloro-2-methylsulphanyl-pyrimido[5,4-d]pyrimidine P-3a (3 g, 14.11 mmol) and nitroaniline A-4a (2.21 g, 14.53 mmol) are placed in dioxane (25 mL) and DIPEA (3.393 mL, 18.34 mmol) and refluxed overnight with stirring. For working up the reaction mixture is evaporated down, the residue is suspended in MeOH, the precipitate formed is filtered off, dried and Z-24a (HPLC-MS: tRet. = 2.05 min; MS (M+H)+ = 329) is obtained.

    [0205] Analogously to the method for synthesising Z-24a further intermediate compounds Z-24 are obtained by reacting components A-4 with P-3a.

    b) Method for synthesising Z-26a:



    [0206] 



    [0207] Z-24a (5 g, 14.47 mmol) is taken up in DCM (50 mL), combined at RT with mCPBA (3.24 g, 14.47 mmol) and stirred for 2 h at RT. The reaction mixture is filtered off, the filtrate is diluted with DCM and washed 3 x with saturated NaHCO3 solution. The organic phase is dried on Na2SO4, filtered off, evaporated down and Z-25a is obtained. Z-25a is further reacted directly without any further purification (content of sulphoxide/sulphone approx. 85 %).

    [0208] Sulphoxide/sulphone Z-25a (85 %, 1 g, 2.47 mmol) and N-methylpiperazine E-3a (4.381 mL, 3.95 mmol) are placed in dioxane (6 mL). TEA (718 µL, 4.94 mmol) is added dropwise to this suspension, then it is heated to 60 °C and stirred for 1 h. For working up the mixture is evaporated down, the residue is suspended with iPrOH/water, filtered and dried. The precipitate is purified by chromatography on NP with DCM/MeOH (9:1) and Z-26a (HPLC-MS: tRet. = 1.96 min; MS (M+H)+ = 381) is obtained.

    [0209] Analogously to the method for synthesising Z-26a further intermediate compounds Z-26 are obtained by oxidation of components Z-24 and reaction with amines E-3. Further intermediate compounds Z-26 are obtained by reacting with alcohols E-3 (in the form of their alkoxides), e.g. with sodium methoxide.

    c) Method for synthesising example compound IV-1:



    [0210] 



    [0211] Nitro compound Z-26a (490 mg, 1.29 mmol) is taken up in EtOH (10 mL), combined with ammonium chloride (34 mg, 0.64 mmol) in water (10 mL) and heated to 60 °C. At this temperature iron powder (719 mg, 12.88 mmol) is added batchwise and the mixture is stirred for a further 1.5 h at 60 °C. After cooling it is filtered through silica gel, washed with DCM/MeOH, the filtrate obtained is dried using the rotary evaporator and Z-27a (HPLC-MS: tRet. = 1.64 min; MS (M+H)+ = 351) is obtained. 4-methoxy-3-trifluoromethylbenzoic acid E-5b (62 mg, 0.29 mmol) is taken up in NMP (750 µL) and combined with DIPEA (166 µL, 1.03 mmol) and HATU (147 mg, 0.39 mmol). After 1 h aniline Z-27a (90 mg, 0.26 mmol) is added and the mixture is stirred at RT. The reaction mixture is purified by preparative HPLC and Example compound IV-1 (HPLC-MS: tRet. = 2.17 min; MS (M+H)+ = 553) is obtained.

    d) Method for synthesising Z-29a:



    [0212] 



    [0213] Nitro compound Z-24a (2.96 g, 9.02 mmol) is taken up in dioxane (100 mL), combined with ammonium chloride (241 mg, 4.51 mmol) in water (100 mL) and heated to 70 °C. At this temperature iron powder (5.04 g, 90.2 mmol) is added batchwise and the mixture is stirred for a further 5 h at 70 °C. After cooling it is filtered through silica gel, washed with DCM/MeOH, the filtrate obtained is dried using the rotary evaporator and Z-28a (HPLC-MS: tRet. = 1.70 min; MS (M+H)+ = 299) is obtained.

    [0214] Benzoic acid E-5c (1 g, 5.29 mmol) is taken up in NMP (10 mL) and combined with DIPEA (3.415 mL, 21.14 mmol) and HATU (3.02 g, 7.93 mmol). After 1 h aniline Z-28a (1.58 g, 5.29 mmol) is added and the mixture is stirred at RT. The reaction mixture is mixed with water. The precipitate formed is filtered off, washed repeatedly with water, then dried and Z-29a (HPLC-MS: tRet. = 2.16 min; MS (M+H)+ = 470) is obtained.

    [0215] Analogously to the method for synthesising Z-29a further intermediate compounds Z-29 are obtained by reduction of components Z-24 and reaction with acids E-5.

    e) Method for synthesising example compound IV-2:



    [0216] 



    [0217] Z-29a (1.91 g, 4.07 mmol) is suspended in DCM (40 mL), combined at 0 °C with mCPBA (950 mg, 4.23 mmol) and stirred for 2 h at RT. The reaction mixture is diluted with DCM and washed 2 x with saturated NaHCO3 solution. The organic phase is dried on Na2SO4, filtered off, evaporated down and Z-30a is obtained.

    [0218] Sulphoxide/sulphone Z-30a (1.39 g, 2.86 mmol) is placed in dioxane (10 mL) and mixed with TEA (1.607 mL, 11.45 mmol). Morpholine E-3b (250 µL, 2.86 mmol) is added dropwise to this suspension, it is heated to 60 °C and stirred for 4 h. For working up the mixture is evaporated down, the residue is dissolved with DMF, purified by preparative HPLC and Example compound IV-2 (HPLC-MS: tRet. = 2.09 min; MS (M+H)+ = 509) is obtained.

    [0219] Analogously to methods a) to c) (synthesis route 2) or a), d) and e) (synthesis route 3) as well as synthesis route 1 shown, besides IV-1 and IV-2 the following compounds IV-3 to IV-68 according to the invention are also prepared (Table 4).
    Table 4


    #StructuretRet. (HPLC) [min]MS (M+H)+
    IV-1

    2.17 553
    IV-2

    2.09 509
    IV-3

    2.17 523
    IV-4

    1.99 501
    IV-5

    2.22 502
    IV-6

    2.40 541
    IV-7

    2.04 522
    IV-8

    2.24 553
    IV-9

    2.16 621
    IV-10

    2.13 515
    IV-11

    2.58 486
    IV-12

    2.19 467
    IV-13

    2.30 566
    IV-14

    2.30 460
    IV-15

    2.31 498
    IV-16

    2.51 543
    IV-17

    2.15 524
    IV-18

    2.24 623
    IV-19

    2.23 517
    IV-20

    2.25 555
    IV-21

    2.54 557
    IV-22

    2.16 538
    IV-23

    2.28 637
    IV-24

    2.27 531
    IV-25

    2.28 569
    IV-26

    2.29 548
    IV-27

    2.14 536
    IV-28

    2.05 536
    IV-29

    2.16 550
    IV-30

    1.98 509
    IV-31

    2.20 537
    IV-32

    1.99 509
    IV-33

    2.26 529
    IV-34

    2.18 511
    IV-35

    2.19 511
    IV-36

    1.93 550
    IV-37

    2.13 523
    IV-38

    2.03 523
    IV-39

    2.40 551
    IV-40*

    1.99 454
    IV-41*

    2.08 447
    IV-42*

    2.12 485
    IV-43*

    2.11 455
    IV-44*

    1.92 433
    IV-45*

    2.18 485
    IV-46*

    2.11 553
    IV-47*

    2.06 535
    IV-48*

    2.17 434
    IV-49*

    2.28 447
    IV-50*

    2.23 489
    IV-51*

    2.11 456
    IV-52*

    1.99 454
    IV-53**

    0.0 497
    IV-54**

    1.78 485
    IV-55**

    1.86 497
    IV-56**

    1.72 471
    IV-57**

    1.59 471
    IV-58**

    1.56 457
    IV-59**

    1.43 511
    IV-60**

    1.60 469
    IV-61**

    1.49 559
    IV-62**

    1.39 499
    IV-63**

    1.49 455
    IV-64**

    1.44 443
    IV-65**

    1.58 457
    IV-66**

    1.29 429
    IV-67

    1.96 621
    IV-68

    1.87 607
    * using NaOMe instead of amines (E-3)
    * by coupling a sulphonic acid instead of carboxylic acid E-5 to the intermediate Z-27



    Example compounds of type V and VI:



    [0220] Compounds of type V and VI are pyrimidopyrimidines monosubstituted in the 8-position (Reaction scheme E).

    [0221] Starting from 4,8-dichloro-pyrimido[5,4-d]pyrimidine P-4a, one chlorine atom is substituted nucleophilically by the aniline components A-1 (synthesis route 1), A-2 (synthesis route 2) or A-3 (synthesis route 3) while the other chlorine atom is reductively removed.

    [0222] The substitution by A-1 or A-2 to obtain the intermediate compounds Z-31 or Z-32 is carried out in comparable manner to the steps illustrated in Reaction scheme A or C (reactions to obtain intermediate compounds Z-2, Z-3, Z-12 or Z-14). Whereas example compounds V may be obtained directly from Z-31 (reduction), saponification and amide coupling with amines E-2 are also necessary in addition to the reduction for the synthesis starting from Z-32.

    [0223] By using the anilines A-3, after reduction of the intermediate compound Z-36, example compounds VI with an inverted amide bond are obtained (regarding the synthesis of A-1 or A-3 cf. the remarks made on Reaction scheme A or B)

    a) Method for synthesising P-4a:



    [0224] 



    [0225] 4,8-dihydroxypyrimidopyrimidine (2.0 g, 12 mmol) is taken. Phosphorus oxychloride (7.0 mL, 76 mmol) and potassium chloride (2.6 g, 35 mmol) are added. Finally, phosphorus pentachloride (6.2 g, 30 mmol) is added batchwise. The reaction mixture is stirred for 1.5 d at 130 °C and 1.5 d at RT. The excess POCl3 is distilled off, the residue is mixed with water and extracted several times with DCM. The combined organic phases are mixed with MgSO4, filtered through silica gel and washed with DCM. The filtrate is slowly evaporated down to about 15 mL. The precipitate formed is suction filtered and P-4a (HPLC-MS: MS (M+H)+ = 200/202/204) is obtained.

    b) Method for synthesizing Z-31a:



    [0226] 



    [0227] 4,8-dichloropyrimidopyrimidine P-4a (100 mg, 0.50 mmol) is placed in THF (2 mL) while cooling with ice. Aniline A-1d (195 mg, 0.50 mmol) and DIPEA (0.1 mL, 0.58 mmol) are added. The reaction mixture is thawed to RT overnight and stirred. For working up it is mixed with a little acetonitrile. The precipitate is filtered off, dried and Z-31a is obtained.

    [0228] Analogously to the method for synthesising Z-31a further intermediate compounds Z-31 are obtained by reacting components A-1 with P-4a.

    c) Method for synthesising Z-32a:



    [0229] 



    [0230] 4,8-dichloropyrimidopyrimidine P-4a (1.0 g, 4.98 mmol) is placed in THF (20 mL) and cooled in the ice bath. Aniline A-2a (840 mg, 4.98 mmol) is added batchwise. The reaction mixture is combined with DIPEA (940 µL, 5.49 mmol) and thawed to RT overnight and stirred. For working up the mixture is evaporated to dryness, taken up in acetonitrile and treated for 5 min in the ultrasound bath. The precipitate is filtered off, washed with a mixture of water and acetonitrile (1:1), dried and Z-32a (HPLC-MS: tRet. = 1.83 min; MS (M+H)+ = 330) is obtained.

    [0231] Analogously to the method for synthesising Z-32a further intermediate compounds Z-32 are obtained by reacting components A-2 with P-4a.

    d) Method for synthesising Z-33a:



    [0232] 



    [0233] Z-32a (1.25 g, 3.79 mmol) is suspended in MeOH (130 mL), combined with Raney nickel and hydrogenated overnight at 2 bar. The reaction mixture is filtered off from the catalyst, evaporated to dryness and Z-33a (HPLC-MS: tRet. = 1.58 min; MS (M+H)+ = 296) is obtained, which is reacted further without any further working up (purity approx. 80 %).

    [0234] Analogously to the method for synthesising Z-33a further intermediate compounds Z-33 are obtained by reduction of intermediate compounds Z-32.

    e) Method for synthesising example compound V-1:



    [0235] 



    [0236] Ester Z-33a (80 %, 817 mg, 2.21 mmol) is combined with a methanolic LiOH solution (270 mg, 11.05 mmol LiOH in 35 mL MeOH). The reaction mixture is stirred overnight at 60 °C. For working up the mixture is diluted with 15 mL water and extracted 1 x with DCM. The aqueous phase is adjusted to an acidic pH with 2N HCl solution and extracted 5 x with EE. The combined organic phases are extracted 1 x with saturated NaCl solution, dried on MgSO4, filtered, evaporated down and Z-34a (HPLC-MS: tRet. = 0.11 min; MS (M+H)+ = 282) is obtained.

    [0237] Benzoic acid Z-34a (462 mg, 1.64 mmol) is suspended in thionyl chloride (10 mL, 134 mmol). The reaction mixture is refluxed for 1 h and stirred overnight at 60 °C. The excess thionyl chloride is spun off and the remainder is dried azeotropically 1 x with toluene. The acid chloride Z-35a is used again directly.

    [0238] 3-amino-5-tert-butylisoxazole E-2d (58 mg, 0.40 mmol) is placed in DCM (4 mL), combined with pyridine (200 µL, 2.47 mmol) and cooled in the ice bath. Then a solution of the acid chloride Z-35a (120 mg, 0.40 mmol) in 3 mL DCM is added. The reaction mixture is stirred for 1 h at RT. For working up the mixture is diluted with water, the DCM is spun off, placed in solution with DMF and chromatographed by RP-MPLC (7 % to 90 % acetonitrile). The product-containing fractions of V-1 (HPLC-MS: tRet. = 1.94 min; MS (M+H)+ = 404) are mixed with 2N HCl solution and freeze-dried.

    [0239] Analogously to the methods a) and c) to e) (synthesis route 2) or the synthesis route 1 shown, besides V-1 the following compounds V-2 to V-10 according to the invention are prepared (Table 5).

    [0240] Compound of type VI is synthesised according to synthesis route 3 shown.
    Table 5


    #StructuretRet. (HPLC) [min]MS (M+H)+
    V-1

    1.94 404
    V-2

    1.37 433
    V-3

    2.17 459
    V-4

    2.04 425
    V-5

    2.01 523
    V-6

    1.78 464
    V-7

    1.96 426
    V-8

    1.25 508
    V-9

    1.04 403
    V-10

    1.07 417



    Example compounds of type VII and VIII:



    [0241] Compounds of type VII and VIII are pyrimidopyrimidines disubstituted in the 4- and 8-position (Reaction scheme F).

    [0242] Starting from 4,8-dichloro-pyrimido[5,4-d]pyrimidine P-4a (synthesis route 4 → Z-37) or the intermediate compounds Z-31, Z-32 or Z-36 (cf. their synthesis from P-4a according to Reaction scheme E) the chlorine atoms in the 4-position are substituted by R3-H (ammonia, methylamine or water/hydroxide). The other reaction steps according to Reaction scheme F correspond to those already described.

    a) Method for synthesising VII-1:



    [0243] 



    [0244] Substance Z-31b (34 %, 141.0 mg, 0.109 mmol) is mixed with methylamine (2M in THF, 1 mL). The reaction mixture is stirred for 20 min at RT. For working up it is evaporated down, the residue is dissolved with DMSO, purified by preparative HPLC and example compound VII-1 (HPLC-MS: tRet. = 1.85 min; MS (M+H)+ = 433) is obtained.

    b) Method for synthesising Z-42a:



    [0245] 



    [0246] 4,8-dichloropyrimidopyrimidine P-4 (2.0 g, 9.95 mmol) is placed in dioxane (40 mL) and cooled in the ice bath. The aniline A-4a (1.514 g, 9.95 mmol) is taken up in 20 mL dioxane and added dropwise to the 4,8-dichloropyrimidopyrimidine solution. Then dipotassium hydrogen phosphate trihydrate (3 M, 6.633 mL, 19.89 mmol) is added. The reaction mixture is heated to RT and stirred overnight at 65 °C. For working up the mixture is cooled and evaporated down. The residue is dissolved in DCM and washed 3 x with water. The organic phase is dried on Na2SO4, filtered off, evaporated down and Z-42a (HPLC-MS: tRet. = 1.81 min; MS (M+H)+ = 317) is obtained.

    c) Method for synthesising Z-43a:



    [0247] 



    [0248] Substance Z-42a (100 mg, 0.32 mmol) is mixed with methylamine (2M in THF, 2 mL). The reaction mixture is stirred for 30 min at RT. The precipitate formed is filtered off, washed with a little THF, dried in vacuo and Z-43a (HPLC-MS: tRet. = 1.68 min; MS (M+H)+ = 312) is obtained.

    d) Method for synthesising VIII-1:



    [0249] 



    [0250] Nitro compound Z-43a (80 mg, 0.26 mmol) is taken up in EtOH (2 mL), mixed with ammonium chloride (7 mg, 0.13 mmol) in water (2 mL) and heated to 75 °C. At this temperature iron powder (72 mg, 1.29 mmol) is added batchwise and the mixture is stirred for a further hour at 75 °C. After cooling it is filtered through silica gel, washed with DCM/MeOH (9:1), the filtrate obtained is dried using the rotary evaporator and Z-44a (HPLC-MS: tRet. = 1.25 min; MS (M+H)+ = 282) is obtained.

    [0251] Benzoic acid E-5c (40 mg, 0.21 mmol) is taken up in DCM (1 mL) and mixed with DIPEA (109 µL, 0.63 mmol) and HATU (88 mg, 0.23 mmol). After 15 min aniline Z-44a (60 mg, 0.21 mmol) is added and the mixture is stirred at RT. For working up the mixture is evaporated down, the residue is dissolved with DMSO, purified by preparative HPLC and example compound VIII-1 (HPLC-MS: tRet. = 1.78 min; MS (M+H)+ = 453) is obtained.
    Table 6


    #StructuretRet. (HPLC) [min]MS (M+H)+
    VII-1

    1.85 433
    VIII-1

    1.78 453
    VIII-2

    1.74 425
    VIII-3

    1.88 439

    Further information on reaction schemes A to F and all the types of example compounds (I to VIII):



    [0252] For synthesising compounds (1) according to the invention the key educts E-1, E-2, E-3, E-4, E-5, A-2 and A-4 are needed, in particular. These starting compounds may be obtained in numerous ways. A significant number of such synthesis components are commercially obtainable or may be prepared by the skilled man using routine methods. In addition, these components and their preparation are known from the prior art or may be carried out routinely analogously to methods known in the prior art or may be expanded into these. These include in particular methods published in the following publications: WO 2004/050642, WO 2005/056535, WO 2005/090333, WO 2005/115991, US 2006/100204, WO 2008/003770, WO 2005/023761, WO 2008/021388, WO 2007/075896, WO 2007/056016, WO 2008/089034, WO 2009/003999 and WO 2009/003998.

    [0253] For educts A-4 there is also the alternative possibility of obtaining them from the aromatic nitro acids A-6 by CURTIUS degradation:



    [0254] For incorporated linker units L2 which are different from -C(O)NH- and -NHC(O)-, the synthesis components required may be converted routinely. Thus, for example, instead of carboxylic acids, sulphonic acids may be used to synthesise the corresponding sulphonamides. Urea linkers are obtained by reacting isocyanates with amines or the compound of two amines via a carbonylbiselectrophil (e.g. CDI, triphosgene).

    [0255] The following Examples describe the biological activity of the compounds according to the invention, without restricting the invention to these Examples.

    [0256] Compounds of general formula (1) are characterised by their many possible applications in the therapeutic field. Particular mention should be made of those applications in which the inhibition of specific signal enzymes, particularly the inhibiting effect on the proliferation of cultivated human tumour cells but also on the proliferation of other cells such as endothelial cells, for example, are involved.

    Kinase test B-RAF (V600E)



    [0257] In a dilution series 10 µL of test substance solution are placed in a multiwell plate. The dilution series is selected so that generally a range of concentrations of 2 µM to 0.119 nM or 0.017 nM is covered. If necessary the initial concentration of 2 µM is changed to 50 µM, 10 µM or 0.4 µM or 0.2857 µM and further dilution is carried out accordingly. The final concentration of DMSO is 5 %. 10 µL of the B-Raf (V600E)-kinase solution are pipetted in (containing 0.5 ng B-Raf (V600E)-kinase in 20 mM Tris-HCl pH 7.5, 0.1 mM EDTA, 0.1 mM EGTA, 0.286 mM sodium orthovanadate, 10 % glycerol, 1 mg/mL bovine serum albumin, 1 mM dithiothreitol) and the mixture is incubated for 24 h at RT under with shaking. The kinase reaction is started by the addition of 20 µL ATP solution [final concentration: 250 µM ATP, 30 mM Tris-HCl pH 7.5, 0.02 % Brij, 0.2 mM sodium orthovanadate, 10 mM magnesium acetate, 0.1 mM EGTA, phosphatase cocktail (Sigma, # P2850, dilution recommended by the manufacturer), 0.1 mM EGTA] and 10 µL MEK1 solution [containing 50 ng biotinylated MEK1 (prepared from purified MEK1 according to standard procedure, e.g. with EZ-Link Sulpho-NHS-LC-Biotin reagent, Pierce, # 21335) and carried out for 60 min at RT with constant shaking. The reaction is stopped by the addition of 12 µL of a 100 mM EDTA solution and incubation is continued for a further 5 min. 55 µL of the reaction solution are transferred into a streptavidin-coated plate (e.g. Streptawell HighBond, Roche, # 11989685001) and shaken gently for 1 h at RT, in order to bind biotinylated MEK1 to the plate. After elimination of the liquid the plate is washed five times with 200 µL of 1x PBS and 100 µL solution of primary antibody plus europium-labelled secondary antibody [Anti Phospho-MEK (Ser217/221), Cell Signaling, # 9121 and Eu-N1 labeled goat-anti-rabbit antibody, Perkin Elmer, # AD0105], the primary antibody is diluted 1:2000 and the secondary antibody is diluted to 0.4-0.5 µg/mL in Delfia Assay Buffer (Perkin Elmer, # 1244-111). After 1 h shaking at RT the solution is poured away and washed five times with 200 µL Delfia Wash Buffer (Perkin Elmer, # 4010-0010/# 1244-114). After the addition of 200 µL Enhancement Solution (Perkin Elmer, # 4001-0010/# 1244-105) the mixture is shaken for 10 min at RT and then measured in a Wallac Victor using the program "Delfia Time Resolved Fluorescence (Europium)". IC50 values are obtained from these dosage-activity curves using a software program (GraphPadPrizm).

    [0258] Table 7 gives the IC50 values determined for the compounds according to the invention using the above B-RAF-kinase test.
    Table 7
    #IC50 [nM] #IC50 [nM] #IC50 [nM]
    I-1 26   I-55 <1   II-13 7
    I-2 9   I-56 <1   II-14 4
    I-3 9   I-57 <1   II-15 40
    I-4 7   I-58 1   II-16 45
    I-5 5   I-59 1   II-17 13
    I-6 68   I-60 <1   II-18 9
    I-7 3   I-61 <1   II-19 9
    I-8 2   I-62 2   III-1 2
    I-9 3   I-63 1   III-2 <1
    I-10 1   I-64 <1   III-3 118
    I-11 1   I-65 <1   III-4 2
    I-12 2   I-66 <1   III-5 2
    I-13 4   I-67 3   III-6 7
    I-14 3   I-68 <1   III-7 1
    I-15 1   I-69 2   III-8 3
    I-16 1   I-70 3   III-9 7
    I-17 1   I-71 7   III-10 6
    I-18 3   I-72 12   III-11 4
    I-19 57   I-73 2   III-12 2
    I-20 50   I-74 3   III-13 9
    I-21 22   I-75 54   III-14 3
    I-22 13   I-76 1   III-15 5
    I-23 14   I-77 2   III-16 2
    I-24 9   I-78 8   III-17 3
    I-25 3   I-79 19   III-18 4
    I-26 70   I-80 2   III-19 1
    I-27 83   I-81 3   III-20 3
    I-28 13   I-82 676   III-21 3
    I-29 15   I-83 2203   III-22 6
    I-30 35   I-84 11   III-23 7
    I-31 58   I-85 7   III-24 5
    I-32 14   I-86 4   III-25 2
    I-33 12   I-87 9   III-26 24
    I-34 2   I-88 10   III-27 8
    I-35 2   II-1 26   III-28 3
    I-36 4   II-2 41   III-29 2
    I-37 4   II-3 50   III-30 2
    I-38 6   II-4 81   III-31 <1
    I-39 5   II-5 50   III-32 1
    I-40 3   II-6 96   III-33 1
    I-41 5   II-7 15   III-34 2
    I-42 9   II-8 2   III-35 5
    I-43 4   II-9 24   III-36 3
    I-52 55   II-10 25   III-37 4
    I-53 21   II-11 20   III-38 5
    I-54 5   II-12 7   III-39 2
    III-40 2   III-88 5   III-136 3
    III-41 1   III-89 4   III-137 3
    III-42 64   III-90 5   III-138 <1
    III-43 972   III-91 1   III-139 3
    III-44 >2000   III-92 1   III-140 5
    III-45 283   III-93 1   III-141 2
    III-46 451   III-94 6   III-142 3
    III-47 95   III-95 2   III-143 2
    III-48 >1000   III-96 2   III-144 <1
    III-49 587   III-97 4   III-145 2
    III-50 5   III-98 2   III-146 <1
    III-51 381   III-99 5   III-147 1
    III-52 2231   III-100 4   III-148 1
    III-53 318   III-101 1   III-149 <1
    III-54 543   III-102 4   III-150 2
    III-55 >150   III-103 2   III-151 1
    III-56 1989   III-104 1   III-152 <1
    III-57 1827   III-105 3   III-153 <1
    III-58 88   III-106 2   III-154 4
    III-59 835   III-107 1   III-155 2
    III-60 230   III-108 <1   III-156 <1
    III-61 2242   III-109 2   III-157 3
    III-62 546   III-110 1   III-158 7
    III-63 13   III-111 <1   III-159 5
    III-64 >1000   III-112 2   III-160 3
    III-65 4171   III-113 2   III-161 6
    III-66 1139   III-114 2   III-162 <1
    III-67 5   III-115 2   III-163 9
    III-68 8   III-116 <1   III-164 2
    III-69 6   III-117 2   III-165 <1
    III-70 4   III-118 2   III-166 4
    III-71 3   III-119 3   III-167 5
    III-72 4   III-120 3   III-168 <1
    III-73 4   III-121 2   III-169 1
    III-74 1   III-122 2   III-170 <1
    III-75 1   III-123 <1   III-171 3
    III-76 11   III-124 3   III-172 2
    III-77 2   III-125 4   III-173 1
    III-78 2   III-126 <1   III-174 2
    III-79 1   III-127 3   III-175 <1
    III-80 6   III-128 3   III-176 4
    III-81 2   III-129 2   III-177 4
    III-82 20   III-130 3   III-178 2
    III-83 8   III-131 2   III-179 >7000
    III-84 2   III-132 <1   III-180 3
    III-85 7   III-133 <1   III-181 17
    III-86 <1   III-134 2   III-182 245
    III-87 3   III-135 4   III-183 >15000
    III-184 2880   III-232 4   III-280 10000
    III-185 >15000   III-233 571   III-281 5
    III-186 26   III-234 15   III-282 1400
    III-187 >2000   III-235 2   III-283 3
    III-188 104   III-236 1124   III-284 3
    III-189 >15000   III-237 2   III-285 274
    III-190 1535   III-238 87   III-286 3
    III-191 >15000   III-239 6   III-287 1
    III-192 2   III-240 4   III-288 2
    III-193 >15000   III-241 48   III-289 13
    III-194 >2000   III-242 19   III-290 1
    III-195 59   III-243 <1   III-291 21
    III-196 16   III-244 <1   III-292 36
    III-197 >15000   III-245 460   III-293 7
    III-198 11   III-246 29   III-294 1
    III-199 23   III-247 1   III-295 17
    III-200 971   III-248 2   III-296 198
    III-201 >10000   III-249 10   III-297 1
    III-202 >2000   III-250 40   III-298 1
    III-203 >10000   III-251 19   III-299 5
    III-204 4   III-252 8   III-300 4
    III-205 >2000   III-253 269   III-301 <1
    III-206 2   III-254 2000   III-302 115
    III-207 11   III-255 23   III-303 7
    III-208 >2000   III-256 15000   III-304 <1
    III-209 162   III-257 61   III-305 2
    III-210 >2000   III-258 15000   III-306 4
    III-211 4   III-259 505   III-307 114
    III-212 >15000   III-260 2000   III-308 47
    III-213 3   III-261 <1   III-309 4
    III-214 56   III-262 9   III-310 50
    III-215 >10000   III-263 15   III-311 2
    III-216 3   III-264 2600   III-312 27
    III-217 2   III-265 4   III-313 200
    III-218 293   III-266 1   III-314 9
    III-219 8   III-267 836   III-315 <1
    III-220 5   III-268 120   III-316 3
    III-221 171   III-269 33   III-317 14
    III-222 <1   III-270 20   III-318 2
    III-223 15   III-271 10   III-319 1
    III-224 <1   III-272 2   III-320 2
    III-225 2   III-273 31   III-321 <1
    III-226 101   III-274 3   III-322 1
    III-227 41   III-275 2   III-323 11
    III-228 5   III-276 6   III-324 55
    III-229 1   III-277 23   III-325 1400
    III-230 6   III-278 88   III-326 292
    III-231 29   III-279 6   III-327 56
    III-328 442   III-378 8   III-426 <1
    III-329 17   III-379 6   III-427 2
    III-330 6   III-380 1400   III-428 <1
    III-331 10   III-381 3   III-429 2
    III-332 4   III-382 <1   III-430 7
    III-333 56   III-383 4   III-431 3
    III-334 10   III-384 2   III-432 6
    III-335 8   III-385 2   III-433 7
    III-336 140   III-386 1   III-435 1
    III-337 2   III-387 2   III-436 2
    III-338 41   III-388 <1   III-437 2
    III-339 1   III-389 <1   III-438 6
    III-340 4   III-390 <1   III-439 4
    III-341 <1   III-391 1   III-440 272
    III-342 2121   III-392 3   III-441 2
    III-343 2   III-393 1   III-442 1
    III-344 7   III-394 1   III-443 1
    III-345 1   III-395 4   III-444 4
    III-346 7000   III-396 3   III-445 2
    III-347 1   III-397 4   III-446 6
    III-348 <1   III-398 1   III-447 13
    III-349 <1   III-399 2   III-448 8
    III-350 <1   III-400 4   III-449 3
    III-351 <1   III-401 3   III-450 3
    III-353 <1   III-402 2   III-454 4
    III-354 20   III-403 3   III-455 8
    III-355 <1   III-404 6   III-456 3
    III-356 <1   III-405 5   III-457 4
    III-357 <1   III-406 3   III-458 1
    III-358 1   III-407 10   III-459 2
    III-359 2   III-408 25   III-460 4
    III-360 3   III-409 9   III-461 2
    III-361 2   III-410 1   III-462 1
    III-362 3   III-411 3   III-463 2
    III-363 <1   III-412 5   III-465 2
    III-364 <1   III-413 <1   III-467 2
    III-365 1   III-414 7   III-468 <1
    III-366 6   III-415 3   III-469 <1
    III-367 2   III-416 1   III-470 2
    III-368 14   III-417 <1   III-471 4
    III-369 2   III-418 2   III-472 2
    III-370 1   III-419 1   III-473 1
    III-372 5   III-420 1   III-474 1
    III-373 8   III-421 12   III-476 17
    III-374 2000   III-422 5   III-480 4
    III-375 2000   III-423 <1   III-481 1
    III-376 7   III-424 6   III-482 4
    III-377 4   III-425 7   III-483 1
    III-484 3   III-533 6   III-587 65
    III-485 3   III-534 106   III-591 1
    III-486 4   III-535 4   III-592 <1
    III-487 13   III-536 1   III-593 1
    III-488 6   III-537 12   III-594 1
    III-489 1   III-538 10   III-595 1
    III-490 2   III-539 2   III-596 2
    III-491 2   III-540 5   III-597 5
    III-492 2   III-541 15   III-598 <1
    III-493 5   III-542 12   III-599 1
    III-494 4   III-543 3   III-600 3
    III-495 2   III-544 1   III-601 6
    III-496 2   III-545 2   III-602 9
    III-497 2   III-546 4   III-603 1
    III-499 3   III-547 <1   III-604 3
    III-500 <1   III-548 3   III-605 6
    III-501 25   III-549 8   III-606 3
    III-502 8   III-550 4   III-607 1
    III-503 1   III-551 1   III-608 7
    III-504 2   III-552 17   IV-1 13
    III-505 49   III-553 2   IV-2 <1
    III-506 4   III-554 3   IV-3 12
    III-507 1   III-555 18   IV-4 44
    III-508 3   III-556 7   IV-5 129
    III-509 5   III-557 4   IV-7 1
    III-510 <1   III-558 23   IV-10 221
    III-511 4   III-559 14   IV-12 1
    III-512 2   III-560 7   IV-13 3
    III-513 1   III-561 9   IV-15 3
    III-514 1   III-562 1   IV-18 9
    III-515 <1   III-563 2   IV-22 2
    III-516 <1   III-564 1   IV-23 4
    III-517 3   III-565 11   IV-24 72
    III-518 2   III-567 2   IV-26 2
    III-519 <1   III-568 1   IV-27 1
    III-520 2   III-569 2   IV-28 1
    III-521 2   III-570 <1   IV-29 1
    III-522 3   III-571 2   IV-30 <1
    III-523 1   III-572 1   IV-31 5
    III-524 3   III-575 3   IV-32 1
    III-525 3   III-577 2   IV-33 2
    III-526 4   III-580 28   IV-34 2
    III-527 <1   III-581 33   IV-35 2
    III-528 2   III-582 74   IV-36 4
    III-529 3   III-583 32   IV-37 1
    III-530 582   III-584 18   IV-38 2
    III-531 13   III-585 27   IV-39 4
    III-532 2   III-586 193   IV-40 2
    #IC50 [nM]
    IV-42 13
    IV-46 3
    IV-50 59
    IV-53 10000
    IV-54 10000
    IV-55 10000
    IV-56 10000
    IV-57 10000
    IV-58 49
    IV-59 2000
    IV-60 2000
    IV-61 10000
    IV-62 2000
    IV-63 595
    IV-64 521
    IV-65 2000
    IV-66 10000
    IV-67 2
    IV-68 3
    V-1 2
    V-8 4
    V-9 5
    V-10 14
    VII-1 1
    VIII-1 <1
    VIII-2 30
    VIII-3 13

    Measurement of the inhibition of the proliferation of cultivated human melanoma cells (SK-MEL-28, B-RAFV600E mutated)



    [0259] For measuring the proliferation of cultivated human tumour cells, cells of the melanoma cell line SK-MEL-28 [American Type Culture Collection (ATCC)] are cultivated in MEM medium, supplemented with 10 % foetal calf serum, 2 % sodium bicarbonate, 1 mM sodium pyruvate, 1 % non-essential amino acids (e.g. from Cambrex, # BE13-114E) and 2 mM glutamine. SK-MEL28 cells are placed in 96-well flat bottomed dishes in a density of 2500 cells per well in supplemented MEM medium (see above) and incubated overnight in an incubator (at 37°C and 5 % CO2). The active substances are added to the cells in different concentrations, so that a concentration range of 50 µM to 3.2 nM is covered. If necessary the initial concentration of 50 µM is changed to 10 µM or 2 µM and further dilution is carried out accordingly (to 0.6 nM or 0.12 nM). After an incubation period of a further 72 h 20 µL AlamarBlue reagent (Serotec Ltd., # BUF012B) are added to each well and the cells are incubated for a further 3-6 h. The colour change of the AlamarBlue reagent is determined in a fluorescence spectrophotometer (e.g. Gemini, Molecular Devices). EC50 values are calculated using a software program (GraphPadPrizm).

    Measurement of the inhibition of the proliferation of cultivated human melanoma cells (A375, B-RAFV600E mutated)



    [0260] For measuring the proliferation of cultivated human tumour cells, cells of the melanoma cell line A375 [American Type Culture Collection (ATCC)] are cultivated in DMEM medium, supplemented with 10 % foetal calf serum and 2 % sodium bicarbonate. Test substances are tested on A375 cells according to the procedure described for SK-MEL28 cells (see above), but seeding them at 5000 cells per well.

    [0261] Most of the example compounds of types I to VIII (Tables 1 to 6) show good to very good activity in the cellular A375 and SK-MEL-28 proliferation test, i.e. an EC50 value of less than 5 µM, generally less than 1 µM.

    [0262] The active substances are characterised in that they have a significantly lower antiproliferative effect on cell lines that do not have a B-RAF mutation, i.e. the EC50 value is generally higher, by a factor of 10, than the EC50 value of B-RAF mutated cell lines.

    [0263] The cellular selectivity of the active substances is demonstrated by the fact that the EC50 value of the phospho-ERK reduction correlates with the EC50 value of the antiproliferative activity in B-RAF mutated cell lines.

    Measurement of the reduction in the phospho-ERK signal in cultivated human melanoma cells (SK-MEL-28, B-RAFV600E mutated)



    [0264] In order to measure the reduction in the phospho-ERK signal of cultivated human tumour cells, cells of the melanoma cell line SK-MEL-28 [American Type Culture Collection (ATCC)] are cultivated in MEM medium, supplemented with 10 % foetal calf serum, 2 % sodium bicarbonate, 1 mM sodium pyruvate, 1 % non-essential amino acids (e.g. from Cambrex, # BE13-114E) and 2 mM glutamine. SK-MEL28 cells are placed in 96-well flat bottomed dishes at a density of 7500 cells per well in supplemented MEM medium (see above) and incubated overnight in an incubator (at 37°C and 5 % CO2). The active substances are added to the cells in different concentrations, so that a concentration range of 10 µM to 2.4 nM is covered. If necessary the initial concentration of 10 µM is changed to 50 µM or 2.5 µM and further dilution is carried out accordingly (to 12.2 nM or 0.6 nM). After an incubation period of a further 2 h the cells are fixed with 4 % formaldehyde and rendered permeable with 0.1 % Triton X-100 in PBS. Non-specific antibody binding is reduced by incubation with 5 % skimmed milk powder dissolved in TBS-T. Phosphorylated ERK is detected with a mouse monoclonal anti-diphosphorylated ERK1/2 antibody (from Sigma, #M8159). After washing steps with 0.1 % Tween 20 in PBS the bound first antibody is detected by the second antibody (peroxidase coupled polyclonal rabbit anti mouse IgG from DAKO #P0161). After further washing steps, the substrate (TMB Peroxidase Substrate Solution from Bender MedSystems #BMS406) is added. The colour reaction is stopped after a few minutes with 1 M phosphoric acid. The colour is measured with a Spectra max Plus reader from Molecular Devices at 450 nm. EC50 values are calculated using a software program (GraphPadPrizm).

    [0265] The substances of the present invention are B-RAF-kinase inhibitors. As can be demonstrated by DNA staining followed by FACS or Cellomics Array Scan analysis, the inhibition of proliferation achieved by means of the compounds according to the invention is brought about above all by preventing entry into the DNA synthesis phase. The treated cells arrest in the G1 phase of the cell cycle.

    [0266] Accordingly, the compounds according to the invention are also tested on other tumour cells. For example these compounds are effective on the colon carcinoma line, e.g. Colo205, and may be used in this and other indications. This demonstrates the usefulness of the compounds according to the invention for the treatment of different types of tumours.

    [0267] On the basis of their biological properties the compounds of general formula (1) according to the invention, their tautomers, racemates, enantiomers, diastereomers, mixtures thereof and the salts of all the above-mentioned forms are suitable for treating diseases characterised by excessive or abnormal cell proliferation.

    [0268] Such diseases include for example: viral infections (e.g. HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphomas and solid tumours (e.g. carcinomas and sarcomas), skin diseases (e.g. psoriasis); diseases based on hyperplasia which are characterised by an increase in the number of cells (e.g. fibroblasts, hepatocytes, bones and bone marrow cells, cartilage or smooth muscle cells or epithelial cells (e.g. endometrial hyperplasia)); bone diseases and cardiovascular diseases (e.g. restenosis and hypertrophy). They are also suitable for protecting proliferating cells (e.g. hair, intestinal, blood and progenitor cells) from DNA damage caused by radiation, UV treatment and/or cytostatic treatment.

    [0269] For example, the following cancers may be treated with compounds according to the invention, without being restricted thereto: brain tumours such as for example acoustic neurinoma, astrocytomas such as pilocytic astrocytomas, fibrillary astrocytoma, protoplasmic astrocytoma, gemistocytary astrocytoma, anaplastic astrocytoma and glioblastoma, brain lymphomas, brain metastases, hypophyseal tumour such as prolactinoma, HGH (human growth hormone) producing tumour and ACTH producing tumour (adrenocorticotropic hormone), craniopharyngiomas, medulloblastomas, meningeomas and oligodendrogliomas; nerve tumours (neoplasms) such as for example tumours of the vegetative nervous system such as neuroblastoma sympathicum, ganglioneuroma, paraganglioma (pheochromocytoma, chromaffinoma) and glomus-caroticum tumour, tumours on the peripheral nervous system such as amputation neuroma, neurofibroma, neurinoma (neurilemmoma, Schwannoma) and malignant Schwannoma, as well as tumours of the central nervous system such as brain and bone marrow tumours; intestinal cancer such as for example carcinoma of the rectum, colon, anus, small intestine and duodenum; eyelid tumours such as basalioma or basal cell carcinoma; pancreatic cancer or carcinoma of the pancreas; bladder cancer or carcinoma of the bladder; lung cancer (bronchial carcinoma) such as for example small-cell bronchial carcinomas (oat cell carcinomas) and non-small cell bronchial carcinomas such as plate epithelial carcinomas, adenocarcinomas and large-cell bronchial carcinomas; breast cancer such as for example mammary carcinoma such as infiltrating ductal carcinoma, colloid carcinoma, lobular invasive carcinoma, tubular carcinoma, adenocystic carcinoma and papillary carcinoma; non-Hodgkin's lymphomas (NHL) such as for example Burkitt's lymphoma, low-malignancy non-Hodgkin's lymphomas (NHL) and mucosis fungoides; uterine cancer or endometrial carcinoma or corpus carcinoma; CUP syndrome (Cancer of Unknown Primary); ovarian cancer or ovarian carcinoma such as mucinous, endometrial or serous cancer; gall bladder cancer; bile duct cancer such as for example Klatskin tumour; testicular cancer such as for example seminomas and non-seminomas; lymphoma (lymphosarcoma) such as for example malignant lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas (NHL) such as chronic lymphatic leukaemia, leukaemic reticuloendotheliosis, immunocytoma, plasmocytoma (multiple myeloma), immunoblastoma, Burkitt's lymphoma, T-zone mycosis fungoides, large-cell anaplastic lymphoblastoma and lymphoblastoma; laryngeal cancer such as for example tumours of the vocal cords, supraglottal, glottal and subglottal laryngeal tumours; bone cancer such as for example osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, osteoma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, giant cell tumour, chondrosarcoma, osteosarcoma, Ewing's sarcoma, reticulo-sarcoma, plasmocytoma, fibrous dysplasia, juvenile bone cysts and aneurysmatic bone cysts; head and neck tumours such as for example tumours of the lips, tongue, floor of the mouth, oral cavity, gums, palate, salivary glands, throat, nasal cavity, paranasal sinuses, larynx and middle ear; liver cancer such as for example liver cell carcinoma or hepatocellular carcinoma (HCC); leukaemias, such as for example acute leukaemias such as acute lymphatic/lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML); chronic leukaemias such as chronic lymphatic leukaemia (CLL), chronic myeloid leukaemia (CML); stomach cancer or gastric carcinoma such as for example papillary, tubular and mucinous adenocarcinoma, signet ring cell carcinoma, adenosquamous carcinoma, small-cell carcinoma and undifferentiated carcinoma; melanomas such as for example superficially spreading, nodular, lentigo-maligna and acral-lentiginous melanoma; renal cancer such as for example kidney cell carcinoma or hypernephroma or Grawitz's tumour; oesophageal cancer or carcinoma of the oesophagus; penile cancer; prostate cancer; throat cancer or carcinomas of the pharynx such as for example nasopharynx carcinomas, oropharynx carcinomas and hypopharynx carcinomas; retinoblastoma such as for example vaginal cancer or vaginal carcinoma; plate epithelial carcinomas, adenocarcinomas, in situ carcinomas, malignant melanomas and sarcomas; thyroid carcinomas such as for example papillary, follicular and medullary thyroid carcinoma, as well as anaplastic carcinomas; spinalioma, epidormoid carcinoma and plate epithelial carcinoma of the skin; thymomas, cancer of the urethra and cancer of the vulva.

    [0270] The new compounds may be used for the prevention, short-term or long-term treatment of the above-mentioned diseases, optionally also in combination with radiotherapy or other "state-of-the-art" compounds, such as e.g. cytostatic or cytotoxic substances, cell proliferation inhibitors, anti-angiogenic substances, steroids or antibodies.

    [0271] The compounds of general formula (1) may be used on their own or in combination with other active substances according to the invention, optionally also in combination with other pharmacologically active substances.

    [0272] Chemotherapeutic agents which may be administered in combination with the compounds according to the invention, include, without being restricted thereto, hormones, hormone analogues and antihormones (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g. goserelin acetate, luprolide), inhibitors of growth factors (growth factors such as for example "platelet derived growth factor" and "hepatocyte growth factor", inhibitors are for example "growth factor" antibodies, "growth factor receptor" antibodies and tyrosinekinase inhibitors, such as for example cetuximab, gefitinib, imatinib, lapatinib and trastuzumab); antimetabolites (e.g. antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5-fluorouracil, capecitabin and gemcitabin, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine, fludarabine); antitumour antibiotics (e.g. anthracyclins such as doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum derivatives (e.g. Cisplatin, oxaliplatin, carboplatin); alkylation agents (e.g. Estramustin, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazin, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas such as for example carmustin and lomustin, thiotepa); antimitotic agents (e.g. Vinca alkaloids such as for example vinblastine, vindesin, vinorelbin and vincristine; and taxanes such as paclitaxel, docetaxel); topoisomerase inhibitors (e.g. epipodophyllotoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantron) and various chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon alpha, leucovorin, rituximab, procarbazine, levamisole, mesna, mitotane, pamidronate and porfimer.

    [0273] Suitable preparations include for example tablets, capsules, suppositories, solutions - particularly solutions for injection (s.c., i.v., i.m.) and infusion - elixirs, emulsions or dispersible powders. The content of the pharmaceutically active compound(s) should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage range specified below. The doses specified may, if necessary, be given several times a day.

    [0274] Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.

    [0275] Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.

    [0276] Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.

    [0277] Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.

    [0278] Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
    Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.

    [0279] Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).

    [0280] The preparations are administered by the usual methods, preferably by oral or transdermal route, most preferably by oral route. For oral administration the tablets may, of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.

    [0281] For parenteral use, solutions of the active substances with suitable liquid carriers may be used.

    [0282] The dosage for intravenous use is from 1 - 1000 mg per hour, preferably between 5 and 500 mg per hour.
    However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.

    [0283] The formulation examples which follow illustrate the present invention without restricting its scope:

    Examples of pharmaceutical formulations



    [0284] 
    A)Tabletsper tablet
      active substance according to formula (1) 100 mg
      lactose 140 mg
      corn starch 240 mg
      polyvinylpyrrolidone 15 mg
      magnesium stearate 5 mg
        500 mg


    [0285] The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.
    B)Tabletsper tablet
      active substance according to formula (1) 80 mg
      lactose 55 mg
      corn starch 190 mg
      microcrystalline cellulose 35 mg
      polyvinylpyrrolidone 15 mg
      sodium-carboxymethyl starch 23 mg
      magnesium stearate 2 mg
        400 mg


    [0286] The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

    C) Ampoule solution



    [0287] 
    active substance according to formula (1) 50 mg
    sodium chloride 50 mg
    water for inj. 5 mL


    [0288] The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.


    Claims

    1. Compounds of general formula (1)

    wherein

    R1 denotes hydrogen or a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
    or
    a suitable substituent, selected from among -ORc, -SRc, -NRcRc, -NRgNRcRc and -S(O)Rc;

    R2 denotes a group optionally substituted by one or more identical or different Rb and/or

    Rc, selected from among C6-10aryl and 5-12 membered heteroaryl;

    R3 is selected from among hydrogen, C1-4alkyl, halogen, -OH, -O(C1-4alkyl), -NH2, -NH(C1-4alkyl) and -N(C1-4alkyl)2;

    R4 denotes fluorine, bromine, chlorine or methyl;

    X1, X2 and X3 each denote CH;

    L1 is selected from among -CH2-, -NH-, -NMe-, -O- and -S-;

    L2 is selected from among -C(O)NH- and -NHC(O)-;

    each Rb is a suitable substituent and is selected independently of one another from among -ORc, -SRc, -NRcRc, -ONRcRc, -N(ORc)Rc, -NRgNRcRc, halogen, -CN, -NO2, -N3, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -C(O)NRgNRcRc, -C(O)NRgRc, -C(NRg)Rc, -N=CRcRc, -C(NRg)ORc, -C(NRg)NRcRc, -C(NRg)NRgNRcRc, -C(NORg)Rc, -C(NORg)NRcRc, -C(NNRgRg)Rc, -OS(O)Rc, -OS(O)ORc, -OS(O)NRcRc, -OS(O)2Rc, -OS(O)2ORc, -OS(O)2NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OC(NRg)Rc, -OC(NRg)NRcRc, -ONRgC(O)Rc, -S(O)Rc, -S(O)ORc, -S(O)NRcRc, -S(O)2Rc, -S(O)2ORc, -S(O)2NRcRc, -NRgC(O)Rc, -NRgC(O)ORc, -NRgC(O)NRcRc, -NRgC(O)NRgNRcRc, -NRgC(NRg)Rc, -N=CRcNRcRc, -NRgC(NRg)ORc, -NRgC(NRg)NRcRc, -NRgC(NORg)Rc, -NRgS(O)Rc, -NRgS(O)ORc, -NRgS(O)2Rc, -NRgS(O)20Rc, -NRgS(O)2NRcRc, -NRgNRgC(O)Rc, -NRgNRgC(O)NRcRc, -NRgNRgC(NRg)Rc and -N(OR9)C(O)Rc and the bivalent substituents =O, =S, =NRg, =NORg, =NNRgRg and =NNRgC(O)NRgRg, while these bivalent substituents may only be substituents in non-aromatic ring systems;

    each Rc independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd and/or Re, selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rd is a suitable substituent and is selected independently of one another from among -ORe, -SRe, -NReRe, -ONReRe, -N(ORe)Re, -N(Rg)NReRe, halogen, -CN, -NO, -NO2, -N3, -C(O)Re, -C(O)ORe, -C(O)NReRe, -C(O)NRgNReRe, -C(O)NRgORe, -C(NRg)Re, -N=CReRe, -C(NRg)ORe, -C(NRg)NReRe, -C(NRg)NRgNReRe, -C(NORg)Re, -C(NORg)NReRe, -C(NNRgRg)Re, -OS(O)Re, -OS(O)ORe, -OS(O)NReRe, -OS(O)2Re, -OS(O)2ORe, -OS(O)2NReRe, -OC(O)Re, -OC(O)ORe, -OC(O)NReRe, -OC(NRg)Re, -OC(NRg)NReRe, -ONRgC(O)Re, -S(O)Re, -S(O)ORe, -S(O)NReRe, -S(O)2Re, -S(O)2ORe, -S(O)2NReRe, -NRgC(O)Re, -NRgC(O)ORe, -NRgC(O)NReRe, -NRgC(O)NRgNReRe, -NRgC(NRg)Re, -N=CReNReRe, -NRgC(NRg)ORe, -NRgC(NRg)NReRe, -NRgC(NRg)SRe, -NRgC(NORg)Re, -NRgS(O)Re, -NRgS(O)ORe, -NRgS(O)2Re, -NRgS(O)2ORe, -NRgS(O)2NReRe, -NRgNRgC(O)Re, -NRgNRgC(O)NReRe, -NRgNRgC(NRg)Re and -N(ORg)C(O)Re and the bivalent substituents =O, =S, =NRg, =NORg, =NNRgRg and =NNRgC(O)NRgRg, while these bivalent substituents may only be substituents in non-aromatic ring systems;

    each Re independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rf and/or Rg, selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rf is a suitable substituent and is selected independently of one another from among -OR9, -SRg, -NRgRg, -ONRgRg, -N(ORg)Rg, -N(Rh)NRgRg, halogen, -CN, -NO2, -N3,-C(O)Rg, -C(O)OR9, -C(O)NRgRg, -C(O)NRhNRgRg, -C(O)NRhORg, -C(NRh)Rg,-N=CRgRg, -C(NRh)ORg, -C(NRh)NRgRg, -C(NRh)NRhNRgRg, -C(NORh)Rg, -C(NORh)NRgRg, -C(NNRhRh)Rg, -OS(O)Rg, -OS(O)ORg, -OS(O)NRgRg, -OS(O)2Rg, -OS(O)2ORg, -OS(O)2NRgRg, -OC(O)Rg, -OC(O)ORg, -OC(O)NRgRg, -OC(NRh)Rg, -OC(NRh)NRgRg, -ONRhC(O)Rg, -S(O)Rg, -S(O)OR9, -S(O)NRgRg, -S(O)2Rg, -S(O)2ORg, -S(O)2NRgRg, -NRhC(O)Rg, -NRhC(O)ORg, -NRhC(O)NRgRg, -NRhC(O)NRhNRgRg, -NRhC(NRh)Rg, -N=CRgNRgRg, -NRhC(NRh)ORg, -NRhC(NRh)NRgRg, -NRhC(NORh)Rg, -NRhS(O)Rg, -NRhS(O)ORg, -NRhS(O)2Rg, -NRhS(O)2ORg, -NRhS(O)2NRgRg, -NRhNRhC(O)Rg, -NRhNRhC(O)NRgRg, -NRhNRhC(NRh)Rg and -N(ORh)C(O)Rg and the bivalent substituents =O, =S, =NRh, =NORh, =NNRhRh and =NNRhC(O)NRhRh, while these bivalent substituents may only be substituents in non-aromatic ring systems;

    each Rg independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rh, selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rh is selected independently of one another from among hydrogen, C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    while the compounds (1) may optionally also be present in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures thereof, or also as pharmacologically acceptable salts of all the above-mentioned forms.


     
    2. Compounds according to claim 1, wherein
    R1 is a group optionally substituted by one or more identical or different Rb and/or Rc, selected from among 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl, and Rb and Rc are defined as in claim 1.
     
    3. Compounds according to claim 2, wherein
    R1 is a 3-7 membered, monocyclic and nitrogen-containing heterocycloalkyl or 6-10 membered, bicyclic and nitrogen-containing heterocycloalkyl optionally substituted by one or more identical or different Rb and/or Rc,
    R1 is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom,
    and Rb and Rc are defined as in claim 1.
     
    4. Compounds according to claim 2 or 3,
    wherein R1 is heterocycloalkyl, which is bound to the pyrimido[5,4-d]pyrimidine structure via a nitrogen atom and is optionally substituted by one or more substituents, each independently selected from among Rb1 and Rc1;

    each Rb1 is selected independently of one another from among -ORc1, -NRc1Rc1, halogen, -C(O)Rc1 and =O, wherein the latter substituent may only be a substituent in non-aromatic ring systems,

    each Rc1 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd1 and/or Re1, selected from among C1-6alkyl, phenyl, C3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,

    each Rd1 is selected independently of one another from among -ORe1 and -NRe1Re1,

    each Re1 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different C1-6alkyl, selected from among C1-6alkyl, C3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.


     
    5. Compounds according to claim 1, wherein
    R1 denotes -NRc2Rc3 and
    Rc2 and Rc3 are each defined as Rc in claim 1.
     
    6. Compounds according to claim 5, wherein
    R1 denotes -NRc2Rc3 and
    Rc2 is selected from among hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl, 5-6 membered heteroaryl and 3-7 membered heterocycloalkyl,
    Rc3 is a group optionally substituted by one or more identical or different Rd3 and/or Re3, selected from among C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl and 3-14 membered heterocycloalkyl,
    each Rd3 is selected independently of one another from among halogen, -NRe3Re3 and -ORe3,
    each Re3 independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rf3 and/or Rg3, selected from among C1-6alkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl,
    each Rf3 denotes -ORg3 and
    each Rg3 is selected independently of one another from among hydrogen and C1-6alkyl.
     
    7. Compounds according to one of claims 1 to 6,
    wherein R2 is a heteroaryl which is selected from among furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, triazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl and pyrimidyl, and is optionally substituted by one or two substituents, each independently selected from among C3-7cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, 1-methylpropyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, 1-methylbutyl, 1-ethylpropyl, isopentyl, Neopentyl, trifluoromethyl, difluoromethyl, fluoromethyl, tert.-butoxy, trifluoromethoxy,




     
    8. Compounds according to one of claims 1 to 6, wherein
    R2 denotes a phenyl

    R5 is selected from among hydrogen, C1-6alkyl, -OC1-6alkyl, C1-6haloalkyl, -OC1-6haloalkyl, C3-7cycloalkyl and 3-7 membered heterocycloalkyl, all the above-mentioned groups optionally being substituted by C1-6alkyl, -CN or -OH;

    R6 is selected from among hydrogen, C1-6alkyl, -OC1-6alkyl, C1-6haloalkyl, -OC1-6haloalkyl, -CN, -OH, halogen, -NHC1-6alkyl and -N(C1-6alkyl)2, the latter two optionally being substituted in the alkyl moiety by a substituent -N(C1-6alkyl)2;

    R7 is selected from among hydrogen, -OC1-6alkyl, halogen, -NHS(O)2C1-6alkyl, -S(O)2NH2, -S(O)2NHC1-6alkyl, -S(O)2N(C1-6alkyl)2,



    R9 is selected from among hydrogen and C1-6alkyl;

    Rc4 denotes hydrogen or a group optionally substituted by one or more identical or different Rd4 and/or Re4, selected from among C1-6alkyl and 3-14 membered heterocycloalkyl;

    each Rd4 is a suitable substituent and is selected independently of one another from among -ORe4, -NRe4Re4 and halogen;

    each Re4 independently of one another denote hydrogen or a group optionally substituted by one or more identical or different Rf4 and/or Rg4, selected from among C1-6alkyl, C1-6haloalkyl, C3-10cycloalkyl, C6-10aryl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rf4 is a suitable substituent and is selected independently of one another from among -ORg4, -NRg4Rg4 and halogen as well as the bivalent substituent =O, which may only be a substituent in non-aromatic ring systems;

    each Rg4 independently of one another denote hydrogen or a group optionally substituted by one or more identical or different Rh4, selected from among C1-6alkyl, C3-10cycloalkyl, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl;

    each Rh4 is selected independently of one another from among C1-6alkyl and the bivalent substituent =O, which may only be a substituent in non-aromatic ring systems;
    or

    the group -NR9Rc4 denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among Rd4 and Re4; the group -NR9Re4 denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) selected from among Rf4 and Rg4; the group -NR9Rg4 denotes a nitrogen-containing, 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different group(s) Rh4; and

    R8 is selected from among hydrogen, C1-6alkyl, -OC1-6alkyl, -CN, halogen, 5-12 membered heteroaryl and 3-14 membered heterocycloalkyl.


     
    9. Compounds according to claim 8, wherein
    R5 is selected from among






     
    10. Compounds - or the pharmacologically acceptable salts thereof - of general formula (1) according to one of claims 1 to 9 for use as medicaments.
     
    11. Pharmaceutical preparations, containing as active substance one or more compounds of general formula (1) according to one of claims 1 to 9 or the pharmacologically acceptable salts thereof, optionally in combination with conventional excipients and/or carriers.
     
    12. Compounds of general formula (1) according to one of claims 1 to 9 for use in the treatment and/or prevention of cancer, infections, inflammations and autoimmune diseases.
     
    13. Compounds according to claim 12 for use in the treatment and/or prevention of cancer.
     
    14. Pharmaceutical preparation comprising a compound of general formula (1) according to one of claims 1 to 9, wherein the compounds (1) may optionally also be present in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures thereof, or also as pharmacologically acceptable salts of all the above-mentioned forms, and at least one other cytostatic or cytotoxic active substance different from formula (1).
     


    Ansprüche

    1. Verbindungen der allgemeinen Formel (1)

    wobei

    R1 Wasserstoff bezeichnet oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rb und/oder Rc, ausgewählt aus C1-6-Alkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl,
    oder
    einem geeigneten Substituenten, ausgewählt aus -ORc, -SRc, -NRcRc, -NRgNRcRc und -S(O)Rc,

    R2 bezeichnet eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rb und/oder Rc, ausgewählt aus C6-10-Aryl und 5-12-gliedrigem Heteroaryl;

    R3 ist ausgewählt aus Wasserstoff, C1-4-Alkyl, Halogen, -OH, -O(C1-4-Alkyl), -NH2, -NH(C1-4-Alkyl) und -N(C1-4-Alkyl)2,

    R4 bezeichnet Fluor, Brom, Chlor oder Methyl;

    X1, X2 und X3 bezeichnen jeweils CH;

    L1 ist ausgewählt aus -CH2-, -NH-, -NMe-, -O- und -S-;

    L2 ist ausgewählt aus -C(O)NH- und -NHC(O)-;

    jedes Rb ist ein geeigneter Substituent und ist unabhängig voneinander ausgewählt aus -ORc, -SRc, -NRcRc, -ONRcRc, -N(ORc)Rc, -NRgNRcRc, Halogen, -CN, -NO2, -N3, -C(O)Rc, -C(O)ORc, -C(O)NRcRc, -C(O)NRgNRcRc, -C(O)NRgORc, -C(NRg)Rc, -N=CRcRc, -C(NRg)ORc, -C(NRg)NRcRc, -C(NRg)NRgNRcRc, -C(NORg)Rc, -C(NORg)NRcRc, -C(NNRgRg)Rc, -OS(O)Rc, -OS(O)ORc, -OS(O)NRcRc, -OS(O)2Rc, -OS(O)2ORc, -OS(O)2NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OC(NRg)Rc, -OC(NRg)NRcRc, -ONRgC(O)Rc, -S(O)Rc, -S(O)ORc, -S(O)NRcRc, -S(O)2Rc, -S(O)2ORc, -S(O)2NRcRc, -NRgC(O)Rc, -NRgC(O)ORc, -NRgC(O)NRcRc, -NRgC(O)NRgNRcRc, -NRgC(NRg)Rc, -N=CRcNRcRc, -NRgC(NRg)ORc, -NRgC(NRg)NRcRc, -NRgC(NORg)Rc, -NRgS(O)Rc, -NRgS(O)ORc, -NRgS(O)2Rc, -NRgS(O)2ORc, -NRgS(O)2NRcRc, -NRgNRgC(O)Rc, -NRgNRgC(O)NRcRc, -NRgNRgC(NRg)Rc und -N(ORg)C(O)Rc und den zweiwertigen Substituenten =O, =S, =NRg, =NORg, =NNRgRg und =NNRgC(O)NRgRg, wobei diese zweiwertigen Substituenten nur Substituenten in nicht-aromatischen Ringsystemen sein können;

    jedes Rc bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rd und/oder Re, ausgewählt aus C1-6-Alkyl, 2-6-gliedrigem Heteroalkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl;

    jedes Rd ist ein geeigneter Substituent und ist unabhängig voneinander ausgewählt aus -ORe, -SRe, -NReRe, -ONReRe, -N(ORe)Re, -N(Rg)NReRe, Halogen, -CN, -NO, -NO2, -N3, -C(O)Re, -C(O)ORe, -C(O)NReRe, -C(O)NRgNReRe, -C(O)NR9ORe, -C(NRg)Re, -N=CReRe, -C(NRg)ORe, -C(NRg)NReRe, -C(NRg)NRgNReRe, -C(NORg)Re, -C(NORg)NReRe, -C(NNRgRg)Re, -OS(O)Re, -OS(O)ORe, -OS(O)NReRe, -OS(O)2Re, -OS(O)2ORe, -OS(O)2NReRe, -OC(O)Re, -OC(O)ORe, -OC(O)NReRe, -OC(NRg)Re, -OC(NRg)NReRe, -ONRgC(O)Re, -S(O)Re, -S(O)ORe, -S(O)NReRe, -S(O)2Re, -S(O)2ORe, -S(O)2NReRe, -NRgC(O)Re, -NRgC(O)ORe, -NRgC(O)NReRe, -NRgC(O)NRgNReRe, -NRgC(NRg)Re, -N=CReNReRe, -NRgC(NRg)ORe, -NRgC(NRg)NReRe, -NRgC(NRg)SRe, -NRgC(NORg)Re, -NRgS(O)Re, -NRgS(O)ORe, -NRgS(O)2Re, -NRgS(O)2ORe, -NRgS(O)2NReRe, -NRgNRgC(O)Re, -NRgNRgC(O)NReRe, -NRgNRgC(NRg)Re und -N(ORg)C(O)Re und den zweiwertigen Substituenten =O, =S, =NRg, =NORg, =NNRgRg und =NNRgC(O)NRgRg, wobei diese zweiwertigen Substituenten nur Substituenten in nicht-aromatischen Ringsystemen sein können;

    jedes Re bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rf und/oder Rg, ausgewählt aus C1-6-Alkyl, 2-6-gliedrigem Heteroalkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl;

    jedes Rf ist ein geeigneter Substituent und ist unabhängig voneinander ausgewählt aus -ORg, -SRg, -NRgRg, -ONRgRg, -N(ORg)Rg, -N(Rh)NRgRg, Halogen, -CN, -NO2, -N3, -C(O)Rg, -C(O)OR9, -C(O)NRgRg, -C(O)NRhNRgRg, -C(O)NRhORg, -C(NRh)Rg, -N=CRgRg, -C(NRh)ORg, -C(NRh)NRgRg, -C(NRh)NRhNRgRg, -C(NORh)Rg, -C(NORh)NRgRg, -C(NNRhRh)Rg, -OS(O)Rg, -OS(O)OR9, -OS(O)NR9R9, -OS(O)2Rg, -OS(O)2ORg, -OS(O)2NR9R9, -OC(O)Rg, -OC(O)OR9, -OC(O)NR9R9, -OC(NRh)Rg, -OC(NRh)NRgRg, -ONRhC(O)Rg, -S(O)Rg, -S(O)ORg, -S(O)NRgRg, -S(O)2Rg, -S(O)2ORg, -S(O)2NRgRg, -NRhC(O)Rg, -NRhC(O)ORg, -NRhC(O)NRgRg, -NRhC(O)NRhNRgRg, -NRhC(NRh)Rg, -N=CRgNRgRg, -NRhC(NRh)ORg, -NRhC(NRh)NRgRg, -NRhC(NORh)Rg, -NRhS(O)Rg, -NRhS(O)ORg, -NRhS(O)2Rg, -NRhS(O)2ORg, -NRhS(O)2NRgRg, -NRhNRhC(O)Rg, -NRhNRhC(O)NRgRg, -NRhNRhC(NRh)Rg und -N(ORh)C(O)Rg und den zweiwertigen Substituenten =O, =S, =NRh, =NORh, =NNRhRh und =NNRhC(O)NRhRh, wobei diese zweiwertigen Substituenten nur Substituenten in nicht-aromatischen Ringsystemen sein können;

    jedes Rg bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rh, ausgewählt aus C1-6-Alkyl, 2-6-gliedrigem Heteroalkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl;

    jedes Rh ist unabhängig voneinander ausgewählt aus Wasserstoff, C1-6-Alkyl, 2-6-gliedrigem Heteroalkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl;

    wobei die Verbindungen (1) gegebenenfalls auch in Form ihrer Tautomeren, Racemate, Enantiomeren, Diastereomeren und Mischungen hiervon vorliegen können, oder auch als pharmakologisch akzeptable bzw. annehmbare Salze von allen oben genannten Formen.


     
    2. Verbindungen nach Anspruch 1, wobei
    R1 eine Gruppe darstellt, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rb und/oder Rc, ausgewählt aus 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl,
    und Rb und Rc sind wie in Anspruch 1 definiert.
     
    3. Verbindungen nach Anspruch 2, wobei
    R1 3-7-gliedriges, monocyclisches und Stickstoff-enthaltendes Heterocycloalkyl oder 6-10-gliedriges, bicyclisches und Stickstoff-enthaltendes Heterocycloalkyl darstellt, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rb und/oder Rc,
    R1 ist über ein Stickstoffatom an die Pyrimido[5,4-d]pyrimidin-Struktur gebunden,
    und Rb und Rc sind wie in Anspruch 1 definiert.
     
    4. Verbindungen nach Anspruch 2 oder 3,
    wobei R1 Heterocycloalkyl darstellt, das über ein Stickstoffatom an die Pyrimido[5,4-d]pyrimidin-Struktur gebunden ist und gegebenenfalls mit ein oder mehreren Substituenten substituiert ist, jeweils unabhängig ausgewählt aus Rb1 und Rc1;

    jedes Rb1 ist unabhängig voneinander ausgewählt aus -ORc1, -NRc1Rc1, Halogen, -C(O)Rc1 und =O, wobei der letztere Substituent nur in nicht-aromatischen Ringsystemen ein Substituent sein kann,

    jedes Rc1 bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rd1 und/oder Re1, ausgewählt aus C1-6-Alkyl, Phenyl, C3-10-Cycloalkyl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl,

    jedes Rd1 ist unabhängig voneinander ausgewählt aus -ORe1 und -NRe1Re1,

    jedes Re1 bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen C1-6-Alkyl, ausgewählt aus C1-6-Alkyl, C3-10-Cycloalkyl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl.


     
    5. Verbindungen nach Anspruch 1, wobei
    R1 -NRc2Rc3 bezeichnet und
    Rc2 und Rc3 sind jeweils wie Rc in Anspruch 1 definiert.
     
    6. Verbindungen nach Anspruch 5, wobei
    R1 -NRc2Rc3 bezeichnet und
    Rc2 ausgewählt ist aus Wasserstoff, C1-6-Alkyl, C3-6-Cycloalkyl, Phenyl, 5-6-gliedrigem Heteroaryl und 3-7-gliedrigem Heterocycloalkyl,
    Rc3 ist eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rd3 und/oder Re3, ausgewählt aus C1-6-Alkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl und 3-14-gliedrigem Heterocycloalkyl,
    jedes Rd3 ist unabhängig voneinander ausgewählt aus Halogen, -NRe3Re3 und -ORe3,
    jedes Re3 bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rf3 und/oder Rg3, ausgewählt aus C1-6-Alkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl,
    jedes Rf3 bezeichnet -ORg3 und
    jedes Rg3 ist unabhängig voneinander ausgewählt aus Wasserstoff und C1-6-Alkyl.
     
    7. Verbindungen nach einem der Ansprüche 1 bis 6,
    wobei R2 ein Heteroaryl darstellt, das ausgewählt ist aus Furyl, Thienyl, Pyrrolyl, Oxazolyl, Thiazolyl, Triazolyl, Isoxazolyl, Isothiazolyl, Pyrazolyl, Imidazolyl, Oxadiazolyl, Thiadiazolyl, Pyridyl und Pyrimidyl und gegebenenfalls mit einem oder zwei Substituenten substituiert ist, jeweils unabhängig ausgewählt aus C3-7-Cycloalkyl, Phenyl, 4-7-gliedrigem Heterocycloalkyl, Methyl, Ethyl, n-Propyl, Isopropyl, n-Butyl, 1-Methylpropyl, Isobutyl, sec.-Butyl, tert.-Butyl, n-Pentyl, 1-Methylbutyl, 1-Ethylpropyl, Isopentyl, Neopentyl, Trifluormethyl, Difluormethyl, Fluormethyl, tert.-Butoxy, Trifluormethoxy,




     
    8. Verbindungen nach einem der Ansprüche 1 bis 6, wobei
    R2 ein Phenyl

    bezeichnet;

    R5 ist ausgewählt aus Wasserstoff, C1-6-Alkyl, -OC1-6-Alkyl, C1-6-Haloalkyl, -OC1-6-Haloalkyl, C3-7-Cycloalkyl und 3-7-gliedrigem Heterocycloalkyl, wobei alle oben genannten Gruppen gegebenenfalls mit C1-6-Alkyl, -CN oder -OH substituiert sind;

    R6 ist ausgewählt aus Wasserstoff, C1-6-Alkyl, -OC1-6-Alkyl, C1-6-Haloalkyl, -OC1-6-Haloalkyl, -CN, -OH, Halogen, -NHC1-6-Alkyl und -N(C1-6-Alkyl)2, wobei die letzten zwei gegebenenfalls im Alkylrest mit einem Substituenten -N(C1-6-Alkyl)2 substituiert sind;

    R7 ist ausgewählt aus Wasserstoff, -OC1-6-Alkyl, Halogen, -NHS(O)2C1-6-Alkyl, -S(O)2NH2, -S(O)2NHC1-6-Alkyl, -S(O)2N(C1-6-Alkyl)2,



    R9 ist ausgewählt aus Wasserstoff und C1-6-Alkyl;

    Rc4 bezeichnet Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rd4 und/oder Re4, ausgewählt aus C1-6-Alkyl und 3-14-gliedrigem Heterocycloalkyl;

    jedes Rd4 ist ein geeigneter Substituent und ist unabhängig voneinander ausgewählt aus -ORe4, -NRe4Re4 und Halogen;

    jedes Re4 bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rf4 und/oder Rg4, ausgewählt aus C1-6-Alkyl, C1-6-Haloalkyl, C3-10-Cycloalkyl, C6-10-Aryl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl; jedes Rf4 ist ein geeigneter Substituent und ist unabhängig voneinander ausgewählt aus -ORg4, -NRg4Rg4 und Halogen, wie auch dem zweiwertigen Substituenten =O, der nur in nicht-aromatischen Ringsystemen ein Substituent sein kann; jedes Rg4 bezeichnet unabhängig voneinander Wasserstoff oder eine Gruppe, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Rh4, ausgewählt aus C1-6-Alkyl, C3-10-Cycloalkyl, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl;

    jedes Rh4 ist unabhängig voneinander ausgewählt aus C1-6-Alkyl und dem zweiwertigen Substituenten =O, der nur in nicht-aromatischen Ringsystemen ein Substituent sein kann;

    oder
    die Gruppe -NR9Rc4 bezeichnet ein Stickstoff-enthaltendes, 3-14-gliedriges Heterocycloalkyl oder 5-12-gliedriges Heteroaryl, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Gruppen, ausgewählt aus Rd4 und Re4,

    die Gruppe -NR9Re4 bezeichnet ein Stickstoff-enthaltendes, 3-14-gliedriges Heterocycloalkyl oder 5-12-gliedriges Heteroaryl, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Gruppen, ausgewählt aus Rf4 und Rg4; die Gruppe -NR9Rg4 bezeichnet ein Stickstoff-enthaltendes, 3-14-gliedriges Heterocycloalkyl oder 5-12-gliedriges Heteroaryl, gegebenenfalls substituiert mit ein oder mehreren gleichen oder verschiedenen Gruppen Rh4; und

    R8 ist ausgewählt aus Wasserstoff, C1-6-Alkyl, -OC1-6-Alkyl, -CN, Halogen, 5-12-gliedrigem Heteroaryl und 3-14-gliedrigem Heterocycloalkyl.


     
    9. Verbindungen nach Anspruch 8, wobei
    R5 ausgewählt ist aus






     
    10. Verbindungen - oder die pharmakologisch akzeptablen bzw. annehmbaren Salze hiervon - der allgemeinen Formel (1) nach einem der Ansprüche 1 bis 9 zur Verwendung als Medikamente.
     
    11. Pharmazeutische Zubereitungen, enthaltend als Wirksubstanz ein oder mehrere Verbindungen der allgemeinen Formel (1) nach einem der Ansprüche 1 bis 9 oder die pharmakologisch akzeptablen bzw. annehmbaren Salze hiervon, gegebenenfalls in Kombination mit herkömmlichen Hilfsstoffen und/oder Trägern.
     
    12. Verbindungen der allgemeinen Formel (1) nach einem der Ansprüche 1 bis 9 zur Verwendung in der Behandlung und/oder Vorbeugung bzw. Prävention von Krebs, Infektionen, Entzündungen und Autoimmunerkrankungen.
     
    13. Verbindungen nach Anspruch 12 zur Verwendung in der Behandlung und/oder Vorbeugung bzw. Prävention von Krebs.
     
    14. Pharmazeutische Zubereitung, umfassend eine Verbindung der allgemeinen Formel (1) nach einem der Ansprüche 1 bis 9, wobei die Verbindungen (1) gegebenenfalls auch in Form ihrer Tautomeren, Racemate, Enantiomeren, Diastereomeren und Mischungen hiervon, oder auch als pharmakologisch akzeptable bzw. annehmbare Salze all dieser oben genannten Formen vorliegen können, und mindestens eine andere zytostatisch oder zytotoxisch wirksame Substanz, die unterschiedlich zu Formel (1) ist.
     


    Revendications

    1. Composés de formule générale (1)

    dans lesquels

    R1 représente un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rb et/ou Rc identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe C1-6 halogénoalkyle, un groupe C3-10 cycloalkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons,
    ou
    un substituant approprié sélectionné parmi -ORc, -SRc, -NRcRc, -NRgNRcRc et -S(O)Rc ;

    R2 représente un groupe facultativement substitué par un ou plusieurs Rb et/ou Rc identiques ou différents, sélectionné parmi un groupe C6-10 aryle et un groupe hétéroaryle à 5 à 12 chaînons ;

    R3 est sélectionné parmi un atome d'hydrogène, un groupe C1-4 alkyle, un atome d'halogène, -OH, un groupe -O(C1-4 alkyle), -NH2, un groupe -NH(C1-4 alkyle) et un groupe -N(C1-4 alkyle)2 ;

    R4 représente un atome de fluor, de brome, de chlore ou un méthyle ;

    X1, X2 et X3 représentent chacun CH ;

    L1 est sélectionné parmi -CH2-, -NH-, -NMe-, -O- et -S- ;

    L2 est sélectionné parmi -C(O)NH- et -NHC(O)-, chaque Rb est un substituant approprié et est sélectionné indépendamment des autres parmi -ORc, -SRc, -NRcRc, -ONRcRc, -N(ORc)Rc, -NRgNRcRc, un atome d'halogène, -CN, -NO2, -N3, -C(O)Rc, -C(O)ORc,-C(0)NRcRc, -C(O)NRgNRcRc, -C(O)NRgORc, -C(NRg)Rc,-N=CRcRc, -C(NRg)ORc, -C(NRg)NRcRc, -C(NRg)NRgNRcRc,-C(NORg)Rc, -C(NORg)NRcRc, -C(NNRgRg)Rc, -OS(O)Rc,-OS(O)ORc, -OS(O)NRcRc, -OS(O)2Rc, -OS(O)2ORc,-OS(O)2NRcRc, -OC(O)Rc, -OC(O)ORc, -OC(O)NRcRc, -OC(NRg)Rc, -OC (NRg)NRcRc, -ONRgC(O)Rc, -S(O)Rc, -S(O)ORc, -S(O)NRcRc, -S(O)2Rc, -S(O)2ORc, -S(O)2NRcRc, -NRgC(O)Rc, -NRgC(O)ORc, -NRgC(O)NRcRc, -NRgC(O)NRgNRcRc, -NRgC(NRg)Rc, -N=CRcNRcRc, -NRgC(NRg)ORc, -NRgC(NRg)NRcRc, -NRgC(NORg)Rc, -NRgS(O)Rc, -NRgS(O)ORc, -NRgS(O)2Rc, -NRgS(O)2ORc, -NRgS(O)2NRcRc,-NRgNRgC(O)Rc, -NRgNRgC(0)NRcRc, -NRgNRgC(NRg)Rc et-N(ORg)C(O)Rc et les substituants bivalents =O, =S, =NRg, =NORg, =NNRgRg et =NNRgC(O)NRgRg, ces substituants bivalents ne pouvant être des substituants que dans des systèmes cycliques non aromatiques ;

    chaque Rc représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rd et/ou Re identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe hétéroalkyle à 2 à 6 chaînons, un groupe C1-6 halogénoalkyle, un groupe C3-10 cycloalkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons ;

    chaque Rd est un substituant approprié et est sélectionné indépendamment des autres parmi -ORe, -SRe, -NReRe, -ONReRe, -N(ORe)Re, -N(Rg)NReRe, un atome d'halogène, -CN, -NO, -NO2, -N3, -C(O)Re, -C(O)ORe,-C(O)NReRe, -C(O)NRgNReRe, -C(O)NRgORe, -C(NRg)Re,-N=CReRe, -C(NRg)ORe, -C(NRg)NReRe, -C(NRg)NRgNReRe,-C(NORg)Re, -C(NORg)NReRe, -C(NNRgRg)Re, -OS(O)Re,-OS(O)ORe, -OS(O)NReRe, -OS(O)2Re, -OS(O)2ORe,-OS(O)2NReRe, -OC(O)Re, -OC(O)ORe, -OC(O)NReRe, -OC(NRg)Re, -OC(NRg)NReRe, -ONRgC(O)Re, -S(O)Re, -S(O)ORe, -S(O)NReRe, -S(O)2Re, -S(O)2ORe, -S(O)2NReRe, -NRgC(O)Re, -NRgC(O)ORe, -NRgC(O)NReRe, -NRgC(O)NRgNReRe, -NRgC(NRg)Re, -N=CReNReRe, -NRgC(NRg)ORe, -NRgC(NRg)NReRe, -NRgC(NRg)SRe,-NRgC(NORg)Re, -NRgS(O)Re, -NRgS(O)ORe, -NRgS(O)2Re,-NRgS(O)2ORe, -NRgS(O)2NReRe, -NRgNRgC(O)Re,-NRgNRgC(O)NReRe, -NRgNRgC(NRg)Re et -N(ORg)C(O)Re et les substituants bivalents =O, =S, =NRg, =NORg, =NNRgRg et =NNRgC(O)NRgRg, ces substituants bivalents ne pouvant être des substituants que dans des systèmes cycliques non aromatiques ;

    chaque Re représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rf et/ou Rg identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe hétéroalkyle à 2 à 6 chaînons, un groupe C1-6 halogénoalkyle, un groupe C3-10 cycloalkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons ;

    chaque Rf est un substituant approprié et est sélectionné indépendamment des autres parmi -ORg, -SRg, -NRgRg, -ONRgRg, -N(ORg)Rg, -N(Rh)NRgRg, un atome d'halogène, -CN, -NO2, -N3, -C(O)Rg, -C(O)ORg, - C(O)NRgRg, -C(O)NRhNRgRg, -C(O)NRhORg, -C(NRh)Rg, - N=CRgRg, -C(NRh)ORg, -C(NRh)NRgRg, -C(NRh)NRhNRgRg, - C(NORh)Rg, -C(NORh)NRgRg, -C(NNRhRh)Rg, -OS(O)Rg, - OS(O)ORg, -OS (O)NRgRg, -OS(O)2Rg, -OS(O)2ORg, - OS(O)2NRgRg, -OC(O)Rg, -OC(O)ORg, -OC(O)NRgRg, -OC(NRh)Rg, -OC(NRh)NRgRg, -ONRhC(O)Rg, -S(O)Rg, -S(O)ORg, -S(O)NRgRg, -S(O)2Rg, -S(O)2ORg, -S(O)2NRgRg, -NRhC(O)Rg, -NRhC(O)ORg, -NRhC (O) NRgRg, -NRhC (O)NRhNRgRg, -NRhC (NRh) Rg, -N=CRgNRgRg, -NRhC(NRh)ORg, -NRhC(NRh)NRgRg, -NRhC(NORh)Rg, -NRhS(O)Rg, -NRhS(O)ORg, -NRhS (O)2Rg, -NRhS(O)2ORg, -NRhS(O)2NRgRg, - NRhNRhC(O)Rg, -NRhNRhC(O)NRgRg, -NRhNRhC(NRh)Rg et - N(ORh)C(O)Rg et les substituants bivalents =O, =S, =NRh, =NORh, =NNRhRh et =NNRhC(O)NRhRh, ces substituants bivalents ne pouvant être des substituants que dans des systèmes cycliques non aromatiques ;

    chaque Rg représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rh identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe hétéroalkyle à 2 à 6 chaînons, un groupe C1-6 halogénoalkyle, un groupe C3-10 cycloalkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons ;

    chaque Rh est sélectionné indépendamment des autres parmi un atome d'hydrogène, un groupe C1-6 alkyle, un groupe hétéroalkyle à 2 à 6 chaînons, un groupe C1-6 halogénoalkyle, un groupe C3-10 cycloalkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons ;

    les composés (1) pouvant facultativement se présenter également sous la forme de tautomères, de racémates, d'énantiomères, de diastéréoisomères et de mélanges de ceux-ci, ou également sous la forme de sels pharmacologiquement acceptables de toutes les formes susmentionnées.


     
    2. Composés selon la revendication 1, dans lesquels R1 est un groupe facultativement substitué par un ou plusieurs Rb et/ou Rc identiques ou différents, sélectionné parmi un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons, et Rb et Rc sont tels que définis dans la revendication 1.
     
    3. Composés selon la revendication 2, dans lesquels R1 est un groupe hétérocycloalkyle azoté monocyclique à 3 à 7 chaînons ou un groupe hétérocycloalkyle azoté bicyclique à 6 à 10 chaînons facultativement substitué par un ou plusieurs Rb et/ou Rc identiques ou différents,
    R1 est lié à la structure pyrimido[5,4-d]pyrimidine par l'intermédiaire d'un atome d'azote,
    et Rb et Rc sont tels que définis dans la revendication 1.
     
    4. Composés selon la revendication 2 ou 3,
    dans lesquels R1 est un groupe hétérocycloalkyle, qui est lié à la structure pyrimido[5,4-d]pyrimidine par l'intermédiaire d'un atome d'azote et est facultativement substitué par un ou plusieurs substituants, chacun indépendamment sélectionnés parmi Rb1 et Rc1;
    chaque Rb1 est sélectionné indépendamment des autres parmi -ORc1, -NRc1Rc1, un atome d'halogène, -C(O)Rc1 et =O, le dernier substituant ne pouvant être un substituant que dans des systèmes cycliques non aromatiques,
    chaque Rc1 représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rd1 et/ou Re1 identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe phényle, un groupe C3-10 cycloalkyle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons,
    chaque Rd1 est sélectionné indépendamment des autres parmi un groupe -ORe1 et -NRe1Re1,
    chaque Re1 représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs groupes C1-6 alkyle identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe C3-10 cycloalkyle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons.
     
    5. Composés selon la revendication 1, dans lesquels
    R1 représente -NRc2Rc3 et
    Rc2 et Rc3 sont chacun définis comme Rc dans la revendication 1.
     
    6. Composés selon la revendication 5, dans lesquels
    R1 représente -NRc2Rc3 et
    Rc2 est sélectionné parmi un atome d'hydrogène, un groupe C1-6 alkyle, un groupe C3-6 cycloalkyle, un groupe phényle, un groupe hétéroaryle à 5 à 6 chaînons et un groupe hétérocycloalkyle à 3 à 7 chaînons,
    Rc3 est un groupe facultativement substitué par un ou plusieurs Rd3 et/ou Re3 identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe C1-6 halogénoalkyle, un groupe C3-10 cycloalkyle et un groupe hétérocycloalkyle à 3 à 14 chaînons,
    chaque Rd3 est sélectionné indépendamment des autres parmi un atome d'halogène, -NRe3Re3 et -ORe3,
    chaque Re3 représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rf3 et/ou Rg3 identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons,
    chaque Rf3 représente -ORg3 et
    chaque Rg3 est sélectionné indépendamment des autres parmi un atome d'hydrogène et un groupe C1-6 alkyle.
     
    7. Composés selon l'une des revendications 1 à 6,
    dans lesquels R2 est un groupe hétéroaryle qui est sélectionné parmi les groupes furyle, thiényle, pyrrolyle, oxazolyle, thiazolyle, triazolyle, isoxazolyle, isothiazolyle, pyrazolyle, imidazolyle, oxadiazolyle, thiadiazolyle, pyridyle et pyrimidyle, et est facultativement substitué par un ou deux substituants, chacun indépendamment sélectionnés parmi les groupes C3-7 cycloalkyle, phényle, hétérocycloalkyle à 4 à 7 chaînons, méthyle, éthyle, n-propyle, isopropyle, n-butyle, 1-méthylpropyle, isobutyle, sec-butyle, tert-butyle, n-pentyle, 1-méthylbutyle, 1-éthylpropyle, isopentyle, néopentyle, trifluorométhyle, difluorométhyle, fluorométhyle, tert-butoxy, trifluorométhoxy,




     
    8. Composés selon l'une quelconque des revendications 1 à 6, dans lesquels
    R2 représente un groupe phényle

    R5 est sélectionné parmi un atome d'hydrogène, un groupe C1-6 alkyle, un groupe -O(C1-6 alkyle), un groupe C1-6 halogénoalkyle, un groupe -O(C1-6 halogénoalkyle), un groupe C3-7 cycloalkyle et un groupe hétérocycloalkyle à 3 à 7 chaînons, tous les groupes susmentionnés étant facultativement substitués par un groupe C1-6 alkyle, -CN ou -OH;

    R6 est sélectionné parmi un atome d'hydrogène, un groupe C1-6 alkyle, un groupe -O(C1-6 alkyle), un groupe C1-6 halogénoalkyle, un groupe -O(C1-6 halogénoalkyle), - CN, -OH, un atome d'halogène, un groupe -NH(C1-6 alkyle) et un groupe -N(C1-6 alkyle)2, les deux derniers étant facultativement substitués dans la fraction alkyle par un substituant -N(C1-6 alkyle)2;

    R7 est sélectionné parmi un atome d'hydrogène, un groupe -O(C1-6 alkyle), un atome d'halogène, un groupe - NHS(O)2(C1-6 alkyle), -S(O)2NH2, -S(O)2NH(C1-6 alkyle), - S(O)2N(C1-6 alkyle)2,



    R9 est sélectionné parmi un atome d'hydrogène et un groupe C1-6 alkyle ;

    Rc4 représente un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rd4 et/ou Re4 identiques ou différents, sélectionné parmi un groupe C1-6 alkyle et un groupe hétérocycloalkyle à 3 à 14 chaînons,

    chaque Rd4 est un substituant approprié et est sélectionné indépendamment des autres parmi -ORe4, - NRe4Re4 et un atome d'halogène ;

    chaque Re4 représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rf4 et/ou Rg4 identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe Cl-6 halogénoalkyle, un groupe C3-10 cycloalkyle, un groupe C6-10 aryle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons ;

    chaque Rf4 est un substituant approprié et est sélectionné indépendamment des autres parmi -ORg4, - NRg4Rg4 et un atome d'halogène ainsi que le substituant bivalent =O, qui ne peut être un substituant que dans les systèmes cycliques non aromatiques ;

    chaque Rg4 représente indépendamment des autres un atome d'hydrogène ou un groupe facultativement substitué par un ou plusieurs Rh4 identiques ou différents, sélectionné parmi un groupe C1-6 alkyle, un groupe C3-10 cycloalkyle, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons ;

    chaque Rh4 est sélectionné indépendamment des autres parmi un groupe C1-6 alkyle et le substituant bivalent =O, qui ne peut être un substituant que dans les systèmes cycliques non aromatiques ;
    ou

    le groupe -NR9Rc4 représente un groupe hétérocycloalkyle azoté à 3 à 14 chaînons ou un groupe hétéroaryle à 5 à 12 chaînons, facultativement substitué par un ou plusieurs groupes identiques ou différents sélectionnés parmi Rd4 et Re4;

    le groupe -NR9Re4 représente un groupe hétérocycloalkyle azoté à 3 à 14 chaînons ou un groupe hétéroaryle à 5 à 12 chaînons, facultativement substitué par un ou plusieurs groupes identiques ou différents sélectionnés parmi Rf4 et Rg4 ;

    le groupe -NR9Rg4 représente un groupe hétérocycloalkyle azoté à 3 à 14 chaînons ou un groupe hétéroaryle à 5 à 12 chaînons, facultativement substitué par un ou plusieurs groupes Rh4 identiques ou différents ; et

    R8 est sélectionné parmi un atome d'hydrogène, un groupe C1-6 alkyle, un groupe -O(C1-6 alkyle), -CN, un atome d'halogène, un groupe hétéroaryle à 5 à 12 chaînons et un groupe hétérocycloalkyle à 3 à 14 chaînons.


     
    9. Composés selon la revendication 8, dans lesquels R5 est sélectionné parmi






     
    10. Composés, ou sels pharmacologiquement acceptables de ceux-ci, de formule générale (1) selon l'une quelconque des revendications 1 à 9, pour leur utilisation en tant que médicaments.
     
    11. Préparations pharmaceutiques contenant, en tant que substance active, un ou plusieurs composés de formule générale (1) selon l'une quelconque des revendications 1 à 9 ou les sels pharmacologiquement acceptables de ceux-ci, facultativement en combinaison avec des excipients et/ou véhicules classiques.
     
    12. Composés de formule générale (1) selon l'une quelconque des revendications 1 à 9, pour leur utilisation dans le traitement et/ou la prévention du cancer, des infections, des inflammations et des maladies auto-immunes.
     
    13. Composés selon la revendication 12, pour leur utilisation dans le traitement et/ou la prévention du cancer.
     
    14. Préparation pharmaceutique comprenant un composé de formule générale (1) selon l'une quelconque des revendications 1 à 9, dans laquelle les composés (1) peuvent également être facultativement présents sous la forme de leurs tautomères, racémates, énantiomères, diastéréoisomères et de mélanges de ceux-ci, ou également sous la forme de sels pharmacologiquement acceptables de toutes les formes susmentionnées, et au moins une autre substance active cytostatique ou cytotoxique différente de la formule (1).
     




    REFERENCES CITED IN THE DESCRIPTION



    This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

    Patent documents cited in the description